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Abstract 
 
The incidence of diseases associated with the metabolic syndrome has rapidly 
increased in recent years. The most common of these diseases is Type 2 
Diabetes. Research into ways of alleviating the pathogenicity of Diabetes is 
ongoing, and the increase in diagnosis in recent years has motivated scientists to 
investigate novel risk markers to help predict and prevent Type 2 Diabetes 
Mellitus and the diseases associated with it.  
 
Adiponectin has become an important molecule in this search. Despite being 
released from adipose tissue, adiponectin correlates inversely with body fat in 
humans and animals. It also exhibits important metabolic regulatory functions 
such as glucose regulation and fatty acid catabolism and has been suggested to 
have anti inflammatory properties.  
 
This thesis reviews literature on the adiponectin molecule and aims to explore 
the complex functioning of this adipokine and its relationship to Cardiovascular 
Disease (CVD) and Diabetes. The methodological considerations chapters focus 
on pre analytical and analytical variables that may affect the collection of blood 
and the measurement of the molecule. We observed the molecule to be very 
stable. The measurement of both the high molecular weight (HMW) and total 
adiponectin species were not affected by up to 7 freeze thaw cycles. 
Furthermore, blood processing times and temperatures did not significantly alter 
results. Although the R&D systems adiponectin kits do not advise the use of 
citrated plasma, we validated its use in these kits and although absolute 
concentrations were lower than with EDTA plasma, they were consistently lower 
throughout the measured sample set. Two other commercial kits (Mercodia and 
ALPCO diagnostics) were tested for performance against the R&D systems 
Enzyme Linked Immunosorbent Assay (ELISA) kit. Although there were 
differences between absolute values in each kit, the overall performance of the 
kits were satisfactory as judged by Bland Altman plots.  
 
In the first of the two clinical associations chapters, we report, from a 
prospective study of older British women, no evidence of any association of HMW 
adiponectin (or its ratio to total adiponectin) with incident vascular events and     4 
suggest that circulating concentrations of adiponectin (and its fractions) may be 
more strongly aligned to the risk for Diabetes than to vascular events.   
 
The final study investigates the relationship between B type natriuretic peptide 
(BNP) and adiponectin in Acute Coronary Syndrome (ACS) patients. Adiponectin 
and BNP are both known to be positively associated with risk of poor outcome, 
and with each other, in cross sectional studies. However, serial changes in these 
parameters, following ACS, have not previously been measured. In this study, 
adiponectin and BNP positively correlated at baseline, 7 weeks, and importantly, 
change over 7 weeks in both parameters was significantly correlated. We 
reported that increases in plasma adiponectin (rather than absolute levels) after 
ACS are related to risk of adverse outcome, but that this relationship is not 
independent of BNP levels. Our results allude to a potential direct or indirect 
effect of BNP on adiponectin levels, post ACS; an observation that requires 
further investigation. 
 
In summary, this thesis has shown adiponectin to be a very stable and robust 
analyte in plasma or serum, with good reproducibility within persons and broadly 
between differing assays. Whilst there are clear data linking low adiponectin 
with incident diabetes, our clinical studies show adiponectin has more complex 
associations with vascular disease, perhaps mediated in part by a complex 
interaction with BNP. Further genetic studies are needed to elaborate causal 
association for this complex molecule.     5 
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 Chapter I: 
Introduction 
1.1   The Adiponectin Molecule 
1.1.1     Background Information to the Molecule 
Adiponectin was originally identified, and given different names, by four 
independent groups over a decade ago. It was first discovered by Scherer and 
Lodish (Scherer et al, 1995)) who named it adipocyte complement related 
protein of 30kDa (ACRP30), in a subtractive hybridization screen comparing 
3T3 L1 adipocytes (cloned cell lines from mouse embryos with the ability to 
differentiate into cells resembling adipocytes (Panigrahy et al, 2002)) with 
undifferentiated pre adipocytes. Spiegelman and colleagues (Hu et al, 1996) 
then adopted the same approach but they called the protein they isolated, 
AdipoQ. Human adiponectin, which is 83% the same as the mouse polypeptide, 
was first cloned by Matsuzawa and colleagues (Maeda et al, 1996) who called 
it adipose most abundant gene transcript 1 (apM1). Finally Tomita and 
colleagues (Nakano et al, 1996) employed a very different method by isolating 
adiponectin from human plasma by utilising its affinity for gelatine, thereby 
naming it gelatine binding protein. In this thesis I will refer to the molecule as 
the better known name, adiponectin.   
After the first description of the molecule in 1995 there was a gap in 
literature (Whitehead et al, 2006), and the physiological and 
pathophysiological importance has only been well documented in recent 
years. Greater than 4000 publications have implicated this molecule’s role in 
various pathological states (Shetty et al, 2009). The adiponectin gene encodes 
a secreted protein expressed predominantly in white adipose tissue (WAT) and 
brown adipose tissue (Kadowaki et al, 2005). It circulates at high levels in 
human plasma accounting for approximately 0.01% (0.5 30 ug/mL) of all 
plasma protein in normal individuals (Magkos et al, 2007), ~1000 fold higher 
than other hormones such as leptin and insulin. Gender has an effect on 
concentrations of adiponectin, with females having higher levels than males 
(Xu et al, 2005). It is also well known that adiponectin levels increase with Chapter 1: Introduction    20 
age, however the cause of this is still unknown (Sattar et al, 2008). Sattar and 
Nelson (Sattar et al, 2008) suggest rises in age related adiponectin may be as 
a result of a salvage mechanism against age related illness such as metabolic 
dysfunction, atherosclerosis and other inflammatory conditions. This will be 
discussed later in section 1.2.1 of this chapter on how adiponectin relates to 
cardiovascular disease (CVD) and heart failure. 
 
1.1.2  Structure 
The molecule is a 244 amino acid long adipokine secreted from adipocytes 
(www.RnDSystems.com). The gene product is a 30kD protein (Scherer et al, 
1995), however this is not found in circulation. Adiponectin automatically 
self binds to form larger structures and there are different multimeric forms 
including low molecular weight (LMW) trimers, middle molecular weight 
(MMW) hexamers, high molecular weight (HMW) oligomeric structures and 
finally globular adiponectin (gC1q domain) (Figure 1.1 (Magkos et al, 2007)). It 
has been proposed that this globular fragment is generated by proteolytic 
cleavage of adiponectin multimers by leukocyte elastase secreted from 
activated monocytes and/or neutrophils (Kadowaki et al, 2005); however the 
pathophysiological importance of this cleavage remains to be determined. Chapter 1: Introduction    21 
   
Figure 1.1: The Different Multimeric Forms of Adiponectin  
 
 
 
Magkos et al, 2007 (Curr Opin Clin Nutr Metab Care) 
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1.1.2.1    Monomeric structure 
There are four distinct regions of adiponectin (Figure 1.2). The protein starts 
with a short signal sequence which acts to target the hormone for secretion 
outside the cell, then it leads into a short region that is variable between 
species, followed by an amino acid region that shows similarity with 
collagenous protein, and finally ending with a globular domain. 
 
Figure 1.2: Schematic Diagram Showing the Protein Structure of Adiponectin  
 
             
             1                 17            45                        110                                   247                                                                                                  
 
       
NH2             COOH 
 
 
 
Abbreviations for figure 1.2: COOH, Carboxylic acid; gC1q, Globular domain; 
NH2, Nitrogen di hydroxide (amine group). 
 
Takeuchi et al, 2007 (Med Mol Morphol) 
 
 
1.1.2.2    Higher order structures 
Initially, three adiponectin molecules bind together to form a homotrimer. 
The trimers continue to self associate and form hexamers or dodecamers (Tilg 
et al, 2006). Like the plasma concentration, the relative levels of the higher 
order structures are sexually dimorphic (Xu et al, 2005; Hug et al, 2004), 
where females have increased proportions of the high molecular weight 
forms. The varying forms have altered biological activity and therefore may 
also have separate functions. The gC1q domain and the trimeric forms of 
adiponectin activate AMP Kinase in skeletal muscle and lead to increased fatty 
acid oxidation and reduction in glucose concentrations (15), whereas the 
hexameric and full length HMW forms are thought to activate nuclear factor 
kappa B (NF κB) pathways (Hug et al, 2004). Conflicting literature on this 
association will be discussed in detail below in section 1.4.1. The proportion 
of HMW adiponectin within adipose tissue is higher than in blood plasma 
(Kadowaki et al, 2005), suggesting regulation at the level of secretion is a 
mechanism of adiponectin complex distribution. All isoforms of the molecule 
 Signal                      Collagen like       
 Peptide                      domain             gC1q domain Chapter 1: Introduction    23 
are stable in circulation, do not seem to be able to interconvert and are 
relatively long lived (half life of ~15hrs) (Kadowaki et al, 2005).  
 
 
1.1.2.3  Homology to Tumour Necrosis Factor alpha (TNFα) 
 
Despite there being unrelated protein sequences, the 3 dimensional structure 
of the gC1q domain of adiponectin has a striking homology to TNFα, and has 
been subsequently named as a TNF superfamily member. TNFα is a cytokine 
involved in systemic inflammation and the acute phase response. It induces 
the hepatic expression of acute phase proteins. The molecule seems to 
possess both growth promoting and growth inhibiting properties, as well as 
mastering a self regulatory function. In spite of the lack of homology at the 
primary amino acid sequence level, the structural features between TNFα and 
adiponectin are highly conserved (Scherer et al, 1995) (Figure 1.3 (Schapiro et 
al, 1998)). Both proteins form bell  shaped homotrimeric oligomers, and the 
evolutionary relationship between adiponectin and TNF family proteins 
suggests that the human adiponectin receptor may also be a member of the 
TNF receptor superfamily. 
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Figure 1.3: Crystal Structure of the Globular Domain of Adiponectin (ACRP30 
gC1q domain) and comparison with the TNFα trimer                                                                
 
 
 
The amino terminus of each ACRP30 protomer is labelled. The collagen stalks 
would protrude from these amino termini. The three fold axis is non 
crystallographic. The three colours highlight the fact that both proteins form 
homo trimeric oligomers.                                                               
 
 
 
 
 
Abbreviations for figure 1.3: ACRP30, Adipocyte Complement Related Protein 
of 30kDa; TNFα, Tumour Necrosis Factor Alpha. 
 
 Schapiro et al, 1998 (Current Biology) 
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1.1.3  Receptors and Signaling 
Two receptors have been identified that bind adiponectin: Adipo R1 and Adipo 
R2. AdipoR1 was first identified when encoding cDNA was isolated from human 
skeletal cDNA library by screening for adiponectin binding (Takeuchi et al, 
2007). The AdipoR2 was identified later due to its striking homology to 
AdipoR1. Both are surface membrane proteins (Takeuchi et al, 2007) and have 
homology to G protein  coupled receptors. The receptors have different 
affinities to the various molecular forms of adiponectin. AdipoR1 and AdipoR2 
are found in liver, muscle and adipose tissue in humans; however AdipoR1 is 
predominantly expressed in skeletal muscle whereas AdipoR2 is more 
predominant in the liver (Takeuchi et al, 2007). AdipoR1 is a high affinity 
receptor for globular adiponectin as well as having a lower affinity for full 
length adiponectin. In contrast the AdipoR2 receptor has an equal 
intermediate affinity for globular and full length HMW adiponectin (Takeuchi 
et al, 2007). The receptors affect a very important cellular metabolic rate 
control point, by targeting AMP activated protein Kinase (AMPK), downstream. 
AMPK is a stress induced kinase that is activated in response to depleting 
Adenosine triphosphate (ATP) or increasing Adenosine monophosphate (AMP) 
levels. AMPK activates ATP and generates catabolic processes such as fatty 
acid breakdown and glycolysis and shuts down ATP consuming processes such 
as lipogenesis (Shetty et al, 2009). Expression of these receptors is correlated 
with insulin levels (Kadowaki et al, 2005). A review of studies involving the 
adiponectin receptors suggests that they may have an important role in 
adiponectin physiology. Key findings suggest that changes in expression of 
AdipoR isoforms in skeletal muscle (rather than total circulating adiponectin 
concentrations) may be of physiological importance (Vu et al, 2007), although 
this may reflect a form of “adiponectin resistance” particularly in less healthy 
individuals.  
 More recently, by means of expression cloning, T cadherin has been 
recognized as an adiponectin receptor on vascular endothelial cells and 
smooth muscle (Takeuchi et al, 2007). The expression of this cadherin 
molecule is known to be correlated with atherosclerosis (Tilg et al, 2006), the 
pathogenesis of which adiponectin is thought to have an effect on. T cadherin 
and adiponectin also both show protection against vascular endothelial cell Chapter 1: Introduction    26 
apoptosis which means that they may have overlapping biological properties 
in injured endothelial cells (Tilg et al, 2006). The receptor is a 
glycosylphosphatidylinositol anchored
1 extra cellular protein that binds 
hexameric and HMW adiponectin but not trimeric or globular species (Hug et 
al, 2004). Interestingly the amino acid sequence of T cadherin has been well 
conserved through evolution, suggesting that it may indeed play an important 
role in higher order vertebrates (Tilg et al, 2006). T cadherin lacks a 
cytoplasmic domain, and therefore it is believed that it does not act as a cell 
cell adhesion molecule and is not restricted to cell cell boundaries but is 
rather found over the entire surface membrane (Tilg et al, 2006). The 
molecular mechanisms of any transmission of the adiponectin signal into the 
cytoplasm and nucleus remain unclear. Hug et al (Takeuchi et al, 2007) 
reported that only eukaryotically expressed adiponectin bound to T cadherin, 
implying that there was some post translational modification of the molecule 
critical for binding. Although the understanding of the roles and regulation of 
these modifications is incomplete, it is clear they contribute to adiponectin 
multimerisation and function. The cysteine residue situated in the amino 
terminal variable domain of adiponectin is involved in disulphide bond 
formation, essential for the oligomerisation process (Whitehead et al, 2006). 
Other post translational modifications include hydroxylation of conserved 
proline and lysine residues within the variable and collagenous domain, and 
these lysine residues are further modified by the addition of a 
glucosylgalactosyl group. The structural significance of these modifications 
has not been reported but with a mutation in four of the five genes encoding 
the lysine residues, a significant decrease in the insulin sensitising action of 
adiponectin is seen (Nakano et al, 1996).  
 
Hug’s study (Hug et al, 2004) also suggests that because of its extracellular 
nature, T cadherin may also act as a co receptor for as yet unidentified 
signaling receptors, through which adiponectin transmits metabolic signals. It 
is also  
                                         
 
1 Glycosylphosphatidylinositol anchored proteins (GPI APs) are
 a functionally and structurally diverse family of post 
translationally
 modified membrane proteins found mostly in the outer leaflet
 of the plasma membrane in a variety of 
eukaryotic cells. Although
 the general role of GPI APs remains unclear, they have attracted
 attention because they 
act as enzymes and receptors in cell
 adhesion, differentiation, and host pathogen interactions (Elortza et al, 2003). 
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possible however that T cadherin may be acting as a non signalling decoy 
receptor of adiponectin. More studies of this nature are required to unravel 
the mystery of the T cadherin/adiponectin signal pathway.   
 
Adiponectin is also known to be involved in is the regulation of peroxisome 
proliferator activated receptor (PPAR) activity (Kadowaki et al, 2005). PPARs 
play an important role in cellular functioning including lipid metabolism, cell 
proliferation, differentiation, adipogenesis and inflammatory signalling (Han 
et al, 2008). There exist three different isomers of the PPAR (α, β, ), each 
with its own ligand activators and each being involved in different processes 
within the cell, ranging from transcription mediation to fatty acid storage. For 
example a PPARα agonist increases the expression of adiponectin receptors in 
WAT and a PPAR  agonist increases the amount of high molecular weight 
multimers compared to total adiponectin (Tsuchida et al, 2005). Treatment of 
obese animals by specific PPAR β agonists causes metabolic parameters to 
normalise and results in the reduction of adiposity (Tenenbaum et al, 2005) 
and hence may prevent the development of obesity (Yamauchi et al, 2002). 
 When adiponectin is secreted from WAT it binds to its receptor (AdipoR1 or 
AdipoR2). With this binding it activates AMPK and PPARα (figure 1.4 (Dupont 
et al, 2008)). Ligand bound PPAR forms a heterodimeric complex with the 
retinoid X receptor (RXR) which is capable of binding to specific response 
elements, termed peroxisome proliferator response elements (PPRE) (Figure 
1.5 (Gervois et al, 2007)). This interaction in the promoter region of target 
genes allows the PPAR to regulate gene expression, in particular adiponectin 
gene expression. Therefore, adiponectin is, to some extent self regulatory 
through PPAR. PPARs may repress gene transcription by a mechanism that is 
independent of DNA binding (left of figure 1.5).This mechanism includes 
interference by PPARs with other transcription factor pathways such as those 
involving NFκB, signal transducers and activators of transcription protein 
(STAT), CCAAT/enhancer binding protein (C/EBP), and activator protein 1 
(AP 1), which modulate the expression of genes involved in inflammation 
pathways. In the liver, full length adiponectin activates AMPK, thereby 
reducing the production of molecules involved in gluconeogenesis and 
increasing phosphorylation of acetyl coenzyme A carboxylase (ACC) as well as Chapter 1: Introduction    28 
fatty acid oxidation. In the skeletal muscle both globular and full length 
adiponectin bind to the receptors to activate AMPK and stimulate 
phosphorylation of ACC, fatty acid oxidation and glucose uptake (Kadowaki et 
al, 2005).These cascades both result in decreased triglyceride content and 
increased insulin sensitivity in the cells (Figure 1.6 (Kadowaki et al, 2005)). 
 
 
 
 
Figure 1.4: Diagram Showing the Activation of AMPK and PPAR by Binding of 
Adiponectin to Its Receptors. 
 
 
 
 
Abbreviations for figure 1.4: ADP, adenosine diphosphate; ATP, adenosine triphosphate; TZD, 
Thiazolidinediones; AICAR, aminoimidazole carboxamide ribonucleotide; PGJ2, Prostaglandin 
J2 
 
Dupont et al, 2008 (PPAR Research) 
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Figure 1.5: Diagram Showing the Methods of Repression by the Ligand Bound 
PPAR and Activation by the PPAR RXR Heterodimeric Complex. 
 
 
 
   
 
Abbreviations for figure 1.5: ABCA 1, ATP binding cassette A1; Apo, apolipoprotein; COX 2, 
cyclooxygenase type 2; CPT I, carnitine palmitoyltransferase I; CRP, C reactive protein; ET 1, 
endothelin 1; FABP, adipocyte fatty acid binding protein; FAT, fatty acid translocase; FATP, 
fatty acid transport protein; IL 1, interleukin 1; LPL, lipoprotein lipase; MCP 1, monocyte 
chemoattractant protein 1; MMP 9, matrix metalloproteinase 9; SR B1, scavenger receptor 
class B1; STAT, signal transducer and activator of transcription. 
 
Gervois et al, 2007 (Nat Clin Pract Endocrinol Metab) 
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Figure 1.6: A Depiction of the Role of Adiponectin in Activating AMPK and 
PPARα 
 
 
 
 
 
Abbreviations for figure 1.6: PEPCK, Phosphoenolpyruvate carboxykinase; GLUT4, glucose 
transporter 4; TG, Triglyceride. 
 
Kadowaki et al, 2005 (Endocr Rev) 
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1.1.4 Function 
Adiponectin has a number of diverse roles within the body incorporating 
modulation of a number of metabolic processes. Despite being released from 
adipose tissue, adiponectin correlates inversely with body fat in humans (Cnop 
et al, 2003) and animals (Freubis et al, 2001). It also exhibits important 
metabolic regulatory functions such as glucose regulation and fatty acid 
catabolism and has been suggested to have anti inflammatory properties (24).  
 
1.1.4.1  Adiponectin function in in vitro and animal studies 
 
In 2001, Freubis et al. showed the apparent insulin sensitizing effects of 
adiponectin. Mice were fed either a high fat test meal or were injected with 
fat emulsion, which dramatically increased the amounts of free fatty acid 
levels. By treatment with protease generated globular adiponectin, the 
elevated levels of free fatty acids were significantly lowered. This effect was 
caused in part by the increase in fatty acid oxidation in the muscle. Kadowaki 
and Yamauchi (Kadowaki et al, 2005) also verified the direct insulin 
sensitizing effect of adiponectin in vivo by using an insulin resistant 
lipoatrophic diabetic mouse model that displayed both adiponectin and leptin
2 
deficiency. The test animals were then given a physiological dose of 
recombinant adiponectin and insulin resistance was significantly reduced. 
Moreover, Scherer’s group reported that an acute increase in circulating 
adiponectin levels triggers a brief decrease in basal glucose levels by 
inhibiting both the expression of hepatic gluconeogenic enzymes and the rate 
of endogenous glucose production in wild type and type 2 diabetic mice (Berg 
et al, 2001).  These findings are consistent with the proposal that adiponectin 
sensitises the body to insulin, and perhaps explains higher expression in the 
lean: adiponectin expression in adipose tissue may control glycaemia and 
fatty acid levels in normal physiological circumstances. Yamauchi et al then 
showed that adiponectin increases AMPK and ACC phosphorylation 
                                         
 
2 Leptin is synthesised and secreted by adipose tissue and acts on the brain and peripheral organs to regulate 
appetite and energy balance within our body 
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in muscle, by treating mice with recombinant adiponectin (Yamauchi et al, 
2002). 
 
Their findings showed that both globular and full length adiponectin increased 
AMPK phosphorylation in vivo in a dose dependent manner, with a 2 fold peak 
at 5 minutes, returning to baseline value after 60 minutes. To determine 
whether the AMPK pathway was required for adiponectin effect in muscle 
cells, Yamauchi and colleagues used a catalytically inactive AMPK to 
demonstrate that activation of AMPK is necessary for adiponectin induced 
stimulation of ACC phosphorylation, fatty acid oxidation, glucose uptake and 
lactate production in muscle cells. This experiment links adiponectin to 
weight limitation.  
 
1.1.4.2  Adiponectin and its role in inflammation 
 
Adiponectin may act as a modulator for the endothelial inflammatory 
response by targeting the NF κB pathway. Members of this family of nuclear 
factors are responsible for regulating over 150 target genes, including the 
expression of inflammatory cytokines, chemokines, immunoreceptors, and cell 
adhesion molecules. Because of this, NF κB has often been called a central 
mediator of the human immune response.  
Adiponectin has been reported to act as both an agonist and an antagonist for 
the NF κB pathway. Adiponectin may promote (Tsao et al, 2002; Hug et al, 
2004) or inhibit (Kadowaki et al, 2005; Ouchi et al, 2000) NF κB signalling, 
probably in a context specific manner. This may consequently lead to up 
regulation or down regulation of the inflammatory response in target cells 
depending on the context. Hexameric and larger forms of adiponectin (but not 
the trimeric or globular species) are thought to activate the NF κB pathway 
(Tsao et al, 2002; Hug et al, 2004), in a manner dependent upon 
phosphorylation and degradation of IκB α. Although the significance of this 
activity is unclear, the hexameric and HMW isoforms of adiponectin do inhibit 
apoptosis of endothelial cells (Kobayashi et al, 2004) and NF κB has well 
described antiapoptotic activities (Wang et al, 1998). This suggests 
oligomerisation may have an important role to play in the molecule’s 
biological activity.  Chapter 1: Introduction    33 
On the other hand, adiponectin
 was shown to inhibit TNF α induced nuclear 
factor κB activation
 through the inhibition of IκB phosphorylation (Ouchi et al, 
2000) (Figure 1.7 (Tilg et al, 2006)). Through this suppression adiponectin 
strongly inhibits the expression of adhesion molecules including intracellular 
adhesion molecule 1 (ICAM), vascular
 cellular adhesion molecule 1 (VCAM), 
and E selectin (Kadowaki et al, 2005). Suppression
 of nuclear factor κB by 
adiponectin might also be a major molecular
 mechanism for the inhibition of 
monocyte adhesion to endothelial
 cells, thus preventing atherogenesis as an 
anti inflammatory factor. 
Adiponectin is thought to dampen the early phases of macrophage 
inflammatory responses, acting to inhibit the growth of myelomonocytic 
progenitor cells (Yokota et al, 2000) and decrease the ability of mature 
macrophages to respond to activation (Gervois et al, 2007). Adiponectin also 
inhibits the expression of the
 scavenger receptor class A 1 of macrophages, 
resulting in markedly
 decreased uptake of oxidized low density lipoprotein 
(LDL) by macrophages
 and inhibition of foam cell formation. This is vital in 
fighting the onset of atherosclerosis. Normal LDL in plasma is not oxidized. 
Oxidation of LDL is believed to contribute to the development of 
atherosclerosis (Yokota et al, 2000), a condition where the walls of the 
arteries are damaged and narrowed by deposits of plaque (cholesterol and 
other fatty substances, calcium, fibrin, and cellular wastes), eventually 
blocking off the flow of blood. Macrophage cells preferentially take up 
oxidized LDL, become loaded with lipids, and convert into "foam cells" 
(Aviram et al, 1996) (Figure 1.8 (Chang et al, 1994)). When large numbers of 
foam cells accumulate in the artery they form a plaque. Stenosis (the 
narrowing of the artery) occurs with the proliferation of foam cells. The lipid 
laden plaques become unstable and eventually may rupture resulting in 
Myocardial Infarction.  In addition, in
 smooth muscle cells, adiponectin 
attenuated DNA synthesis
 induced by growth factors (Arita et al, 2002). Some 
important roles adiponectin plays in inflammation are summarised in figure 
1.9 (Iqbal O, 2007). 
 
Okamoto et al used apoE deficient mice to demonstrate that an increase of 
plasma adiponectin suppressed the progression of atherosclerotic lesions 
(Okamoto et al, 2002). They injected a replication  defective adenovirus Chapter 1: Introduction    34 
vector containing full length adiponectin or β galactosidase gene in the tail 
vein of male apoE /  mice. These mice develop vascular lesions similar to 
human atherosclerosis (Plump et al, 1992). After 14 days atherosclerotic 
lesion areas in the full length adiponectin treated mice were reduced by 30% 
compared with the β galactosidase gene treated mice. They also reported a 
decrease in the m RNA levels of VCAM 1 and TNFα. These findings suggest that 
plasma adiponectin may protect endothelial cells from hyper cholesterolemia  
vascular injury, and reduce the uptake of LDL into foam cells. 
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Figure 1.7: Illustrates Adiponectin’s Role in the Inhibition of the NF κB 
Pathway. 
 
Note that adiponectin acts in the inhibition of the TNF α induced NF κB pathway (b). 
 
   
Abbreviations for figure 1.7: AdipoR1, Adiponectin receptor 1; AdipoR2, 
Adiponectin receptor 2; TNFR1, Tumour necrosis factor receptor 1; AMPK, 
amp activated protein kinase; PPAR, peroxisome proliferator activated 
receptor; PPRE, Peroxisome Proliferator Response Element; IκB, IkappaB 
kinase; IFN , Interferon y; IL 10, Interleukin 10; IL 1RA, Interleukin 1 receptor 
antagonist. 
 
Tilg et al, 2006 (Nat Rev Immunol) 
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Figure 1.8: Diagram Showing Oxidation of LDL and Foam Cell Formation 
 
Monocytes migrate from the vascular lumen to the intima where they 
differentiate into macrophages. The scavenger receptors on the surface of 
macrophages take up modified LDLs, forming macrophage foam cells. 
 
 
 
 
Abbreviations for figure 1.8: LDL, Low density Lipoprotein 
 
Chang et al, 1994 (Somat Cell Mol Genet) 
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Figure 1.9: Summarising the Anti Inflammatory Role of Adiponectin 
 
Adiponectin acts in the inhibition of monocyte adhesion to endothelial cells 
and prevents the oxidation of LDL, thus preventing atherogenesis as an anti 
inflammatory factor.  
 
Abbreviations for figure 1.9: LDL, Low density lipoprotein; SR A, Scavenger 
receptor A 
 
Iqbal O, 2007 (Personalized Medicine) 
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1.1.4.3  Associations of Adiponectin with other Risk Factors in Humans 
 
Adiponectin is a very complex hormone and exhibits relationships with a 
number of molecules, and performs a number of diverse roles within our 
body. A few of these processes have been demonstrated by means of in vitro 
and animal studies, but how does the molecule function in humans?  
Since the discovery of the insulin sensitising action of adiponectin in 2001 
(Kadowaki et al, 2006), there has been great interest in the molecule. 
Substantial research has been undertaken with the aim to develop a 
recombinant form of the protein for therapeutic purposes. Clinical studies 
have revealed negative associations with body mass index (BMI), waist to hip 
ratio (WHR), Insulin, glucose, HOMA IR, C reactive protein (CRP) levels and 
triglyceride levels while exhibiting positive associations with High density 
lipoprotein (HDL) Cholesterol and age (Table 1.1 (Sattar et al, 2008). Many 
studies (Ouchi et al, 2007; Pischon et al, 2004; Rathman et al, 2000; 
Wannamethee et al, 2007; Zhuo et al, 2009)) have found similar associations. 
Hu et al first showed that adiponectin may be linked to human obesity (Hu et 
al, 1996) by using northern blots to show that adiponectin expression was 
reduced in adipose tissues of obese mice and humans (Lu et al, 2008). A 
report of an adiponectin immunoassay stimulated activity in the human 
clinical research field (Arita et al, 1999). Using this assay Arita et al 
demonstrated that plasma adiponectin levels were higher in women than in 
men (Lau et al, 2008) and in non obese than obese subjects. These reports 
have subsequently been confirmed by many other studies (Kadowaki et al, 
2006; Whitehead et al, 2005; Hulstrom et al, 2008). Despite adiponectin being 
secreted by adipocytes, circulating levels decrease with obesity. Research 
originally proposed that mechanisms associated with insulin resistance, such 
as inflammation, inhibited the expression of adiponectin in the adipose tissue 
(Lu et al, 2008). Cytokines released in inflammation, which are known to rise 
in obesity, may play a role in the suppression of adiponectin. Recent studies 
in human subjects involving the treatment with PPAR  agonists revealed that 
the plasma adiponectin levels increase 2 fold despite significant body weight 
gain (Lu et al, 2008). This means that adiponectin levels are increasing 
independently of weight and rather due to improvement in adipose specific Chapter 1: Introduction    39 
insulin sensitivity. Therefore it is now thought adiponectin gene expression 
may increase irrespective of changes in adiposity but rather due to adipose 
tissue specific insulin sensitivity (Lu et al, 2008).In line with this Vozarova et 
al showed that hypo adiponectinemia is not the cause of obesity but rather a 
result of obesity induced insulin resistance in the adipose tissue (Vozarova et 
al, 2002). In this study low plasma adiponectin concentrations did not predict 
future weight gain in humans. This result was also seen in animal models 
(Pelleymounter et al, 1995). Therefore it may be leptin, rather than 
adiponectin, that is the hormone primarily responsible for weight regulation. 
Paradoxically to adiponectin, serum levels of leptin increase with weight gain.  
 
Considering the metabolic effects of adiponectin, it is fair to propose that the 
lower levels of adiponectin seen in obese subjects is a direct result of the 
obesity and adipose tissue specific insulin resistance and that these lower 
levels of adiponectin mediate the state of insulin resistance and metabolic 
outcomes in other peripheral tissues. Consistent with the known associations 
of adiponectin with obesity and diabetes, multiple observations now support 
the molecule as a potent antidiabetic hormone. In a number of prospective 
diverse population studies, adiponectin consistently predicts lower risk for 
Type 2 Diabetes (Kadowaki et al, 2005; Sattar et al, 2008; Sattar et al, 2008) 
and as predicted lower adiponectin levels were also reported in many insulin 
resistance related clinical conditions such as polycystic ovary syndrome, non 
alcoholic fatty liver disease, lipodystrophy and human immunodeficiency virus 
(HIV) patients (Lu et al, 2008). 
 
Collectively these observations would suggest that adiponectin is 
predominantly beneficial, leading us to the assumption it may also display 
protective effects in vascular tissue. In 2004 Pischon et al reported an 
outcome in apparent protection against myocardial infarction (MI) (Pischon et 
al, 2004). The initial excitement of these findings later dissipated as 
increasing numbers of published journal articles appeared to quash the idea, 
and the latest literature now shows higher levels of circulating adiponectin 
actually correlate positively to coronary heart disease (CHD) and all cause 
mortality, rather than to apparent protection against CHD (Laughlin et al, 
2007). Some ideas as to the reason for this will be discussed in more detail Chapter 1: Introduction    40 
later on. The relationship between adiponectin and blood pressure seemed to 
be more difficult to demonstrate in human studies, probably due to the 
interference from other metabolic confounding factors related to insulin 
resistance. But results lean towards there being a higher reported blood 
pressure with lower plasma adiponectin levels (Lu et al, 2008). 
Although a large number of studies have researched the complex mechanisms 
of this molecule and its associations with other risk markers, larger studies 
with increased sample numbers are needed to elucidate these potential links. Chapter 1: Introduction    41 
 
Table 1.1: Correlation of High Molecular Weight Adiponectin and Total 
Adiponectin with Measures of Adiposity, Insulin, Glucose and Lipid Levels in 
British Women Aged 60 79 years.  
N = 500 
 
  Spearman’s Rank 
correlation 
coefficient with 
HMW adiponectin 
p  Spearman’s 
Rank correlation 
coefficient with 
total 
adiponectin 
p 
HMW or total 
adiponectin 
0.75  < 0.001  0.75  < 0.001 
Age   0.08  0.07  0.13  0.004 
BMI    0.12  0.008   0.20  < 0.001 
Waist hip 
ratio 
 0.26  < 0.001   0.32  < 0.001 
Insulin 
   0.35  < 0.001   0.41  < 0.001 
Glucose 
   0.11  0.01   0.20  < 0.001 
HOMA IR    0.30  < 0.001   0.38  < 0.001 
CRP   0.17  0.002   0.20  < 0.001 
Total chol.   0.00  0.97   0.02  0.51 
LDL C   0.01  0.84   0.01  0.63 
HDL C  0.37  < 0.001  0.44  < 0.001 
Triglycerides 
   0.34  < 0.001   0.42  < 0.001 
SBP    0.06  0.20   0.05  0.36 
DBP   0.05  0.31  0.01  0.62 
 
Abbreviations for table 1.1: BMI, body mass index; CRP, C reactive protein; 
HOMA IR, Homeostasis model assessment insulin resistance; LDL C, low 
density lipoprotein cholesterol; HDL C, high density lipoprotein cholesterol; 
SBP, systolic blood pressure; DBP, diastolic blood pressure 
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1.2   The Associations of Adiponectin with Incident 
Diabetes Mellitus, Vascular Disease and Mortality  
 
The prevalence of obesity has increased dramatically in recent years, and it is 
commonly associated with Type 2 Diabetes Mellitus, coronary artery disease 
(CAD) and Hypertension, collectively known as the metabolic syndrome 
(Kadowaki et al, 2006). Adipose tissue has been targeted as the prime focus 
for biomedical research associated with obesity and obesity related diseases 
(Vozarova et al, 2002). It is now considered to be a genuine endocrine tissue 
which has the primary role of secretion of molecules into the blood; TNFα, 
Inter Leukin 6 (IL 6), leptin, adiponectin, resistin, visfatin and omentin among 
others, which influence the physiology of organs or tissues at a distant site. 
Understanding the biology of adipose tissue and the rapidly growing list of 
adipokines secreted from it provides new insights into normal physiological 
regulation, as well as the pathogenesis and treatment of obesity, diabetes and 
disorders of lipid metabolism and the cardiovascular system (Ahima et al, 
2008). 
 
1.2.1 Associations with Diabetes Mellitus 
Type 2 diabetes is very common in obese individuals. It is a disorder whereby 
the body still produces insulin but does not produce enough insulin or does not 
utilise the insulin that is produced correctly (insulin resistance (IR)), or a 
combination of these.  The prevalence of the disease worldwide is reaching 
epidemic proportions (Smith et al, 2003) and is said to be fuelled by the 
adoption of a more “westernised” lifestyle incorporating high fat foods and 
including little exercise. IR is a key feature of the metabolic syndrome and 
the diseases associated with it. It is now generally accepted to be the primary 
metabolic defect of Type 2 Diabetes Mellitus (Smith et al, 2003). IR is defined 
as a state that requires more insulin to obtain the biological effects achieved 
by a lower amount of insulin in the normal state (Kadowaki et al, 2006). 
In contrast to other adipokines, circulating levels of adiponectin correlate 
inversely with body fat and IR in humans (Whitehead et al, 2006) and rodent 
models (Kadowaki et al, 2006). Adiponectin is known to increase fatty acid 
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therefore a reduced circulating adiponectin level in the blood may result in 
insulin resistance.  It has been reported that blood concentrations of 
adiponectin fall from 20 50% in humans and mice respectively with the 
administration of insulin, thus implying that the effect of insulin to lower 
adiponectin levels may involve inhibition of adipocyte secretion. Plasma 
adiponectin levels have also been shown to be decreased in an obese rhesus 
monkey model that frequently develops Type 2 Diabetes (Kadowaki et al, 
2006). Many prospective studies (Yatagai et al, 2003; Daimon et al, 2003; 
Spranger et al, 2003; Jalovaara et al, 2008) have shown that lower 
adiponectin levels are associated with a higher incidence of diabetes in 
humans and more importantly the decrease in plasma adiponectin levels was 
in parallel with the decrease in insulin sensitivity (Kadowaki et al, 2006). This 
finding is further supported by a recent meta analysis of 13 prospective 
studies, which found that higher adiponectin levels were monotonically 
associated with a lower risk of Type 2 Diabetes across diverse populations (Li 
et al, 2009) (Figure 1.10 (Li et al, 2009)). 
 Studies (Yu et al, 2002; Miyazaki et al, 2004) have shown that in type 2 
diabetic patients, treatment with medications incorporating thiazolidinedione 
(TZD) enhances insulin action on peripheral glucose disposal (Miyazaki et al, 
2004), reduces hepatic fat content (Yatagai et al, 2003) and decreases 
endogenous glucose production (Yu et al, 2002). Such medications are also 
known as glitazones, and are regarded as insulin sensitizing agents. These 
medications are used in patients with diabetes mellitus where lifestyle 
measures have proved insufficient (Krentz et al, 2006). Plasma adiponectin 
increases substantially in response to glitazone treatment in healthy, obese 
and Type 2 diabetic subjects (Yu et al, 2002; Hulstrom et al, 2008; Miyazaki et 
al, 2004). The insulin sensitizing effects resulting from treatment with 
glitazones are thought to be regulated through PPAR   (Yu et al, 2002) (Figure 
1.11 (Kumar CKA, 2008)). Glitazone treatment results in decreased insulin 
resistance, modified adipocyte differentiation, decrease in leptin levels, a fall 
in certain interleukin levels, and a rise in adiponectin levels (Wang et al, 
2003; Otto et al, 2006). Although it is reasonable to assume that the insulin 
sensitising and antidiabetic effect of TZD is mediated in part by up regulation 
of adiponectin levels, in fact very few studies (Yu et al, 2002; Miyazaki et al, 
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reported an association between increases in adiponectin levels and 
improvements in peripheral and hepatic insulin sensitivity in response to 
treatment with TZD medications. In one of the above mentioned studies, 
Pajvani et al postulates that it may be down to the complex distribution of 
the adiponectin molecule rather than its absolute amount that correlates to 
TZD mediated improvement in insulin sensitivity (Pajvani et al, 2004). They 
report that diabetic patients have a lower HMW/total adiponectin ratio 
compared with healthy lean individuals and suggest that the new HMW/total 
ratio index they describe as SA, would be more useful in cases where 
differences in insulin sensitivity cannot be explained by differences in 
absolute adiponectin serum levels alone. Also, of mention is the fact that 
adiponectin levels increase in normal lean, obese and type 2 diabetic subjects 
(Yu et al, 2002; Hulstrom et al, 2008; Miyazaki et al, 2004) and this indicates 
that adiponectin is unlikely to be the only cause of TZD induced insulin 
sensitivity (Yu et al, 2002). TZD has emerged as a strong therapeutic tool for 
diabetes care, but more studies are needed to investigate the dose response 
effect on adiponectin levels (Yu et al, 2002) and the interactions of glitazones 
with other PPAR   target genes (Hulstrom et al, 2008).  The rise in the amount 
of new cases of diabetes each year makes this an important and essential 
topic of research, which will help to benefit many and add quality to so many 
lives affected by this disease. Chapter 1: Introduction    45 
 
Figure 1.10: Relative Risks Per 1 Log [mu]g/mL of Adiponectin Level and Type 
2 Diabetes Across Studies 
 
 
Fourteen data points are included for the 13 studies because results for men 
and women are shown separately in the Hoorn study (Snijder et al). Size of 
squares corresponds to the weight of each study in the meta analysis.  
 
 
 
 
Abbreviations for figure 1.10: CI, Confidence interval 
 
Li et al, 2009 (JAMA) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter 1: Introduction    46 
 
Figure 1.11: Effects of Thiazolidinedione Medications 
 
 
 
Abbreviations for figure 1.11: PPARץ, Peroxisome Proliferator Activated 
Receptor Gamma; TNFα, Tumour Necrosis Factor Alpha. 
Kumar CKA, 2008 (Recent Pharmaceautical Reviews) 
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1.2.2   Associations with Cardiovascular Disease Events 
There is considerable interest in the vascular actions of adiponectin due to its 
insulin sensitising (Sattar et al, 2006), anti inflammatory (Kadowaki et al, 
2005) and anti atherogenic (von Eynatten et al, 2008) properties. Whilst there 
is consistent evidence that high levels of adiponectin are associated with 
lower risk for diabetes, it remains unclear whether high adiponectin is 
associated with lower risk for CHD events (Sattar et al, 2008). The general 
assumption was that a reduced adiponectin concentration may underlie the 
heightened vascular risk associated with obesity and the metabolic syndrome 
but this association is proving to be more complex that previously thought. In 
animal models, exogenous adiponectin administration protects against 
development of atherosclerosis in apolipoprotein E deficient mice (Yamauchi 
et al, 2003). In humans, however the evidence has been somewhat 
conflicting. The Health Professionals Follow Up Study (HPFUS) (Pischon et al, 
2004) was the first study to publish results of the relationship between CHD 
and adiponectin levels and it noted high adiponectin to be independently 
associated with incidence for myocardial events. They reported that a 
doubling of baseline adiponectin levels was associated with a statistically 
significant 20% reduction in MI after adjustments for confounders, which 
consequently led to the suggestion that adiponectin might be the major 
mechanistic link between diabetes and increased CHD risk. Since then 
however, there have been inconsistencies in the data published on this 
relationship. Some studies (Koenig et al, 2006; Costacou et al, 2005) support 
the understanding that adiponectin is emerging as an important mediator of 
future risk for primary CHD while some more recent studies have not been 
consistent with this analysis (Sattar et al, 2008; Sattar et al, 2006; Lawlor et 
al, 2005; Lindsay et al, 2005; Kizer et al, 2008). A recent meta analysis of 7 
prospective studies encompassing 1313 CHD cases demonstrated significantly 
little, if any, association of a single measurement of adiponectin with a 
combined end point of nonfatal MI and CHD death (Sattar et al, 2008) (Figure 
1.12 (Sattar et al, 2008)). So far it has not been elucidated whether 
adiponectin is a useful prognostic predictor in patients in advanced stages of 
CHD, thus suggesting that the use of adiponectin for cardiovascular risk is 
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relationship of adiponectin to later vascular disease may be less apparent in 
the presence of Type 2 Diabetes or obesity (Lindsay et al, 2005), and he notes 
that studies supporting the notion that decreased adiponectin predicts 
increased risk of CVD, did not include as many participants with diabetes or 
obesity as his study did.  This hypothesis merits further investigation. Chapter 1: Introduction    49 
Figure 1.12: Prospective Studies of Circulating Concentrations of Adiponectin 
and CHD Risk 
 
Abbreviations for figure 1.12: BWWHS, British Womens Heart and Health 
Study; BRHS, British Regional Heart Study; HPFUS, Health Professionals Follow 
up Study, STRONG, Strength Training Ongoing Study; PEDCS, Pittsburgh 
Epidemiology of Diabetes Complication Study. 
 
Sattar et al, 2006 (Circulation) 
 
Zocalli et al.     15     227 
PEDCS                    8              62 
 
 BWHHS     165     334 
 STRONG     251     251 
 HPFUS                  266           532 
 BRHS (new data)  589     1231 
STUDY   CHD 
CASES 
NON- 
CASES 
RISK 
RATIO 
(95%CI) 
 
 
0.25  0.5   1.0   2.0   4.0 
      0 0. .8 84 4   ( (0 0. .7 70 0- -1 1. .0 01 1) )   
Mayo Clinic     19     317 
Total                 1313      2954 
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1.2.2.1 HMW Adiponectin and its associations with incident vascular events 
 
Due to the apparent inconsistencies in the data reported from various studies, 
the separate functioning of the independent parts of the molecule and their 
biological activity were focused on in more detail. The HMW form of 
adiponectin is thought to be the key biologically active form of the molecule 
because it has been shown to be better associated with insulin sensitivity than 
total adiponectin, has been more strongly linked to a lower risk of incident 
diabetes, and it has been linked more strongly to protection against 
endothelial cell apoptosis (Sattar et al, 2008). Commercial ELISA kits for the 
measurement of the HMW fraction became available and this spurred greater 
interest in this form of the molecule. A nested case control from the British 
Women’s Heart and Health Study (BWHHS) found no significant link between 
HMW adiponectin and the risk of incident vascular events, and suggested 
rather that the molecule was more aligned for the determination of risk with 
the incidence of diabetes. Von Eynatten et al confirmed this by suggesting 
from their study that although high total and HMW adiponectin levels were 
associated with a more favourable CHD risk profile, they were not 
significantly associated with future secondary CVD events (von Eynatten, 
2008).These observations suggest that the use of either total or HMW 
adiponectin may add no prognostic value to that gained by established 
cardiovascular risk factors for the occurrence of secondary CVD events (von 
Eynatten, 2008).  
 
1.2.3 Associations with Coronary Heart Failure (CHF) 
 
Studies in people with prevalent heart failure or acute coronary syndrome 
(ACS) show that high plasma levels of adiponectin are associated with greater 
disease severity (McEntegart et al, 2007) (Nakamura et al, 2006) and with 
higher risk of adverse outcome (Tsutamoto et al, 2007) (Kistorp et al, 2005). 
B type natriuretic peptide (BNP) and its inactive N terminal metabolite NT 
proBNP (released in a 1:1 ratio during processing) are sensitive markers of 
cardiac overload and are markers of prognosis in those with CHF (Clerico et 
al, 2004). Several studies have shown positive correlations of circulating 
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coronary artery disease (Cavusoglu et al, 2006) (George et al, 2006)(Kistorp et 
al, 2005) (McEntegart et al, 2007) (Nakamura et al, 2006) (Tsutamoto et al, 
2007) (von Eynatten et al, 2006). Indeed, in the recent Atherogene Study, 
baseline adiponectin predicted risk of poor outcome in CHF independent of 
conventional risk factors, but not independent of BNP (Schnabel et al, 2008). 
A recent study (Ang et al, 2009) also shows a positive correlation between 
baseline circulating BNP and adiponectin. In this study increases in plasma 
adiponectin from baseline, after ACS, to 7 week follow up (rather than 
absolute levels at each time point), were related to risk of adverse outcome. 
Although the patterns of risk associations of BNP and adiponectin are 
different, the data from this study showed that following index admission for 
ACS, BNP and adiponectin associated with each other at baseline, at 7 week 
follow up, and that change in both markers also correlated (r=0.39, p<0.001). 
The results give insight into the pathophysiology behind increased risk of ACS 
recurrence, CHF, or death following an index ACS event. The results are 
suggestive of an interesting and potentially important pathophysiological 
pathway which links an increase in adiponectin to adverse prognosis in a 
manner not independent of BNP.   
 
1.2.4 Associations with CVD Mortality and All Cause Mortality 
 
In some studies, high levels of adiponectin have been shown to predict 
mortality in patients with chronic heart failure (Kistorp et al, 2005; George et 
al, 2006) and in patients presenting with coronary artery disease (CAD) 
(Cavusoglu et al, 2006).  
The British Regional Heart Study (BRHS), one of the largest studies of its kind, 
investigated the relationship between adiponectin levels and all cause 
mortality in elderly men (60 79yrs) with and without CVD (including CHD or 
stroke). The main aim of this study was to determine whether adiponectin 
levels were associated with increased CVD mortality in only those with 
existing vascular disease or heart failure or whether this extended to all 
individuals in a population. The study findings were consistent with that of 
previous studies (Kistorp et al, 2005; George et al, 2006); high adiponectin 
levels are associated with increased mortality in heart failure subjects, but it 
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adiponectin levels and mortality in the general population of men without 
diagnosed CVD or heart failure. This increased mortality was seen for 
cardiovascular and non cardiovascular causes (Wannamethee et al, 2007).  
The Rancho Bernado Study (Laughlin et al, 2007) examined the association of 
adiponectin with CHD prevalence, incidence, and mortality among 1,513 men 
and women aged 50 91 years who were followed from 1984 1987 through to 
2004. The study also examined the associations of adiponectin with CVD and 
all cause mortality. Sex differences were evaluated. Adiponectin 
concentrations were not significantly related to CHD mortality (including after 
adjustments for age, sex, waist girth, HDL, triglycerides and glucose) and 
there was no evidence of a trend across adiponectin quintiles. The nature of 
the adiponectin link to the pathogenesis of CHD and its long term effects is 
not yet clear. 
The study also found that with adiponectin levels in the highest sex specific 
quintile, there was a 40% increased risk of CVD death and all cause mortality 
and this result was independent of age, sex, lipid levels, waist circumference 
and glucose levels. Therefore although high adiponectin levels have been 
linked to a more favourable cardiovascular disease risk profile, there seems to 
be inconsistencies in the fact that high levels seem to be correlated to 
increased CVD and all cause mortality.  
 
1.2.5 Adiponectin vs. Type 2 Diabetes Mellitus and CVD 
mortality: Explaining the paradox 
 
A recent editorial (Sattar et al, 2008) explores suggestions as to why an 
increase in adiponectin levels may be linked to increased CVD mortality. With 
respect to this, a number of suggestions have been explored which include 
renal dysfunction and thereby impaired adiponectin clearance, peripheral 
adiponectin resistance and unintentional weight loss in the elderly. However, 
Kizer et al have now considered and partially dismissed renal dysfunction as a 
potential confounder, and although the study relied on self reported weight 
loss they also included change in this parameter in their analyses and found 
the association was independent of weight loss (Kizer et al, 2008). Evidence 
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in groups at elevated risk, is scarce and this may be an avenue worth 
exploring. 
Sattar and Nelson suggest the possibility that it may be due to reverse 
causality (Sattar et al, 2008), whereby silent or clinically apparent vascular 
disease leads to compensatory rises in adiponectin. As mentioned in section 
1.1 of this overview, adiponectin synthesis has been proposed to be 
stimulated in response to vascular inflammation, however systemic markers of 
inflammation appear to not explain the link between adiponectin and 
mortality (Kizer et al, 2008).  Another suggestion offered by Sattar and Nelson 
is that a rise in B Type/Brain Natriuretic Peptide (BNP) levels may link 
existing vascular disease to higher adiponectin levels because circulating 
levels of these two parameters show positive correlations in patients with and 
without chronic heart failure (McEntegart et al, 2007) (Ang et al, 2009). The 
mechanism is as yet unknown but it has been suggested that high levels of 
adiponectin in those with acute coronary syndrome (ACS) or heart failure may 
be a reflection of a salvage mechanism to improve insulin resistance and fatty 
acid metabolism thereby counteracting vascular stress (McEntegart et al, 
2007). Finally we cannot yet rule out the possibility that higher adiponectin 
levels may actually be harmful to the vasculature and we should bear in mind 
that measures taken to improve diabetes control or protect against its 
pathogenicity do not necessarily lessen CVD risk. In order to drive this field 
forward, future studies are required to better understand the relevance of 
adiponectin to potential interventions. 
 
1.3    Ethnic Variation 
There is evidence of ethnic variation in adiponectin concentrations 
(Retnakaran et al, 2004). People of South Asian descent (defined as Indian, 
Pakistani, Sri Lankan or those having descent from Bangladesh) have an 
increased risk of Type 2 Diabetes Mellitus compared with any other ethnic 
groups studied (Retnakaran et al, 2004; Valsamakis et al, 2003; McKeigue et 
al, 1991). Conventional risk factors associated with the metabolic syndrome 
(hypertension, dyslipidaemia and smoking) do not fully reconcile the elevated 
risk this ethnic group faces. Retnakaran et al proposed that there may be 
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for study is adiponectin, due to its associations with Type 2 Diabetes and CAD. 
Retnakaran et al reported metabolic characteristics of three main ethnic 
groups; Caucasian, Asian and South Asian.  
180 women who were in their late second or early third trimester of 
pregnancy were included in the study. Adjusted median adiponectin levels 
were highest in the Caucasian population, followed closely by the Asians and 
the lowest levels were recorded in the South Asian population (figure 1.13 
(Retnakaran et al, 2004)). Moreover, bearing in mind the inverse relationship 
between adiponectin and BMI, the observed hypoadiponectinaemia observed 
in South Asians is particularly striking, since the Caucasian population 
exhibited a higher mean pregnancy BMI in this study. Similar results were 
reported by Valsamakis et al in 2003, in a totally different study group. The 
paper described a reduced adiponectin concentration in 15 middle aged South 
Asian males compared with BMI matched Caucasians. These findings raise the 
possibility that hypoadiponectinaemia may be a main factor contributing to 
the increased prevalence of diabetes in South Asians (Retnakaran et al, 2004), 
and further strengthen the notion of ethically determined differences in 
adiponectin concentration. Hypoadiponectinaemia is consistent with 
metabolic features associated within this ethnic group. Central obesity is a 
common feature in South Asians (McKeigue et al, 1991), and a recent study 
(Cnop et al, 2003) has shown through body fat distribution analysis, that 
adiponectin correlates with intra abdominal fat rather than subcutaneous fat. 
Also, South Asians exhibit lower levels of HDL cholesterol than Caucasians 
(Bhopal et al, 2002) and as mentioned above there is an independent positive 
association between adiponectin levels and HDL cholesterol. CRP levels have 
also been noted to be higher in South Asians (Forouhi et al, 2001) and 
accordingly since adiponectin is inversely correlated to CRP levels, 
hypoadiponectinaemia could potentially explain the apparent central role of 
visceral adipose tissue in the relationship between low grade inflammation 
and features of the metabolic syndrome in South Asians (Retnakaran et al, 
2004). Retnakaran et al showed that the expected inverse relationship 
between adiponectin and fasting insulin was observed in Caucasians and 
Asians, but not in the South Asian population studied. A plausible explanation 
for this is that ethnically determined hypoadiponectinaemia may obscure the 
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2004).  Another study (Ferris et al, 2005), which reported reduced adiponectin 
levels in black South Africans and Asian Indians compared with BMI matched 
Caucasians, confirmed these same findings (table 1.2). Within each ethnic 
group, adiponectin only correlated inversely with HOMA in Caucasian subjects, 
however when all ethnic groups were combined, multiple regression analysis 
demonstrated that serum adiponectin levels corrected for BMI and ethnicity 
did not correlate with HOMA. Therefore the indication from this particular 
study is that ethnic variation in insulin sensitivity is not dependent on serum 
levels of adiponectin and that the relationship between adiponectin and 
insulin resistance varies across ethnic groups (Ferris et al, 2005). 
 
 
 
 
Figure 1.13: Adjusted Mean Adiponectin in Pregnant Women by Ethnic Group.  
 
Adjusted for age, fasting insulin, glucose intolerance, pre pregnancy body 
mass index, weight gain during pregnancy, previous history of gestational 
diabetes mellitus, and family history of diabetes mellitus 
  
 
 
Retnakaran et al, 2004 ( Diabetic Medicine) Chapter 1: Introduction    56 
Table 1.2 Demographic and biochemical data for Ferris’s Study 
 
Data is expressed as means ± SD; *p < 0.01 versus Asian subjects, † p < 0.01 
versus white subjects.  
Variables  Asian  Black  White 
 
Age (years)              41.5 ± 10.8  36.2 ± 11.3  37.9 ± 9.0 
BMI (kg/m2)  27.3 ±5.0  27.6 ± 5.3  26.2 ± 4.6 
 
Waist to hip ratio  0.86 ±0.09  0.78 ± 0.07*  0.82 ± 0.10* 
 
Triglyceride (mM)  1.77 ±1.15  0.92 ± 0.75*†  1.34 ± 0.88 
 
HDL (mM)  1.29 ± 0.29  1.36 ± 0.32  1.41 ± 0.33 
 
LDL (mM)  3.28 ± 1.06  2.39 ± 0.65*†  3.29 ± 1.05 
 
Cholesterol (mM)  5.33 ± 1.24  4.10 ± 0.76*†  5.30 ± 1.01 
 
Adiponectin 
( g/ml) 
5.86 ± 2.50†  5.71 ± 2.50†  8.11 ± 4.39 
 
HOMA  3.41 ± 2.85†  2.62 ± 0.99†  1.76 ± 0.63 
 
 
Abbreviations for table1.2: BMI, Body Mass Index; HDL, High Density 
Lipoproten; LDL, Low Density Lipoprotein; HOMA, Homeostasis Model 
Assessment 
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1.4  Aims and Objectives of Studies Reported in This 
Thesis  
The aim of the work documented in this thesis was to review literature on, 
and explore the complex functioning of the adiponectin molecule in human 
health and disease. There were two specific aims: i) I considered the 
methodologies behind the collection, processing, measurement and analysis of 
total and HMW adiponectin to assure that future research into this molecule 
within our laboratory and elsewhere was robust, and ii) I examined 
adiponectin’s relationship to CVD both in terms of prediction and subsequent 
outcome following an event. 
   
The role of adiponectin in human health and disease is more complex than 
originally thought and it may be that the molecule exhibits separate 
functioning in times of stress within the body and with normal human health. 
The thesis aims to add insight to this hypothesis. 
 
Chapters three and four focus on Methodological considerations. Many factors 
other than disease influence the results of tests within a laboratory. These 
factors may be pre analytical, analytical or post analytical (or a combination 
of these). Whenever possible, these variables should be controlled in order to 
minimize their effect on test outcome.  Pre analytical variables are variables 
associated with the patient, sample collection and sample handling. These 
generally affect the composition of the body fluid before analysis.  
Analytical variables are factors which influence the analytical procedure and 
post analytical variables involve the different ways data from the laboratory 
is presented, stored and transferred to the clinician. This thesis focuses on 
pre  analytical and analytical variables only. 
 
Chapters five and six report findings from two studies published on work 
carried out within our laboratory or in collaboration with other local research 
facilities, where I had a role in assessment and drafting of relevant articles. 
These chapters focus on the role adiponectin plays in disease. They aim to 
add insight into the complex functioning of the adiponectin molecule with 
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with other molecules that correlate to its levels at different stages in the 
pathogenesis of heart disease.  
 
Aims of Chapter 3.2 – Effect of Freeze/Thaw Cycles 
 
The aim of this study was to investigate the effect of repeated freeze/thaw 
on the amount of measurable concentrations of adiponectin in a blood 
sample. This study is important to ensure that samples are not compromised 
with continual freeze/thaw.  
 
1.4.2  Aims of Chapter 3.3 – Blood Processing 
 
The aim of this study was to determine if leaving bloods un separated (a) in a 
fridge/cold room at 7˚C and (b) on a bench at room  temperature (23˚C   
25˚C) for up to 6 days after venipuncture would have an effect on measurable 
concentrations  of  total  adiponectin  in  EDTA  blood  samples.  This  is  an 
important variable to assess because, at times, it is not possible to get bloods 
from the venue of venipuncture to the laboratory for analysis right away. 
 
1.4.3  Aims of Chapter 3.4 – Biological Variability 
The aim of this study was to investigate biological variation of total 
adiponectin and therefore assess whether total adiponectin levels vary 
significantly in an individual (human) over the period of 6 weeks. 
This information will help where a study may dictate a patient/volunteer to 
give a sample for weekly analysis. It will help to eliminate any variables 
associated with natural biological change in adiponectin concentrations over 
time. 
 
1.4.4 Aims of Chapter 4.2 – Measurement of Citrate Samples on 
a Total  Adiponectin  ELISA 
The aim of this study was to validate samples that have been preserved with 
citrate anticoagulant for use in a total adiponectin R&D systems ELISA assay 
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1.4.5   Aims of Chapter 4.3 – Comparison of Commercial 
Adiponectin ELISA Assays 
The aim of the study was to measure total adiponectin using the ALPCO 
diagnostics ELISA method, the Mercodia adiponectin ELISA method and the 
R&D Systems ELISA method on the same set of samples. I wanted to determine 
whether the results obtained were comparable between methods. 
 
1.4.6   Aims of Chapter 5 - High Molecular Weight Adiponectin 
and Incident Coronary Heart Disease: Findings from a 
Prospective Case Control Study Nested within the British 
Women’s Heart and Health Study (BWHHS) 
This study was designed to test whether HMW adiponectin (rather than the 
previously reported total adiponectin from the original BWHHS (Lawlor et al, 
2005)) was better associated with risk for incident vascular events in older 
women.  There has been some speculation that the HMW fraction of 
adiponectin was the more biologically active part of the molecule. This study 
adds insight to this hypothesis. 
 
1.4.7 Aims of Chapter 6 - Serial Changes in Adiponectin and 
BNP in ACS Patients: Paradoxical Associations with Each Other 
and with Prognosis. 
The aim of this study was to further investigate the potential pathological link 
between BNP and adiponectin. By examining the inter relationship of 
circulating adiponectin and BNP both at baseline and at a 7 week follow up, 
the aim was to determine whether change in either parameter was a better 
predictor of adverse events than a single measurement. Also, changes in 
concentrations of adiponectin over time were investigated to see if they 
correlated with changes in BNP over time. Chapter 2: General Methods    60 
 
                  Chapter II: General 
Methods 
2.1     Review of the Literature 
PubMed (http://www.ncbi.nlm.nih.gov/pubmed/) was used for the purpose of 
literature searches in this thesis. It is a service of the U.S. National Library of 
Medicine that includes over 19 million citations from MEDLINE and other life science 
journals for biomedical articles back to 1948. PubMed includes links to full text 
articles and other related resources (Pubmed online). 
Key word searches were used including: Adiponectin, Adiponectin in: Cardiovascular 
disease, Diabetes, Insulin sensitivity, Health and disease, Heart Failure, Ischemic 
Heart disease, Males, Females, Children.  
Results were restricted to English language, and for epidemiological studies data 
were restricted to human subjects as well.  
The University of Glasgow library and the departmental book shelf (including books 
on related topics and past theses) were used to research books on this topic. 
2.2   Subject Recruitment and Sample storage 
2.2.1  Subject Recruitment 
Each study in this thesis comprises a different sample set and for this reason 
the recruitment of healthy volunteers and patients, venipuncture procedures 
and sample handling and processing are described in detail in each relevant 
chapter. 
2.2.2  Sample Storage 
Accuracy of results is a reflection on the care taken in sample storage. 
All samples used in the studies presented in this thesis are of a high quality 
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own laboratory (Chapters 3+4) are frozen immediately after processing at  
80˚C and removed and snap thawed (37˚C) immediately before assay. 
Samples handled in multi centre laboratories (Chapters 5+6) are done so in a 
standardised manner by professionally trained researchers according to good 
laboratory practice (GLP) 
(http://www.mhra.gov.uk/Howweregulate/Medicines/Inspectionandstandards
/GoodLaboratoryPractice/index.htm). 
2.3  Materials 
Names and addresses of manufacturers and suppliers of kits and reagents, 
hardware and software used for the studies in this thesis are given in the 
appendix 1. All kit inserts are available in appendix 3.  
 
2.4   Laboratory Methods 
2.4.1  Measurement of Total Adiponectin 
2.4.1.1  R&D Systems ELISA Method 
Total Adiponectin concentrations were measured using the R & D Systems 
Quantikine Human Adiponectin/Acrp30 Immunoassay (Catalog Nos DRP300). 
See the R&D systems kit insert in appendix 3 for assay instructions. Specific 
equipment and quality controls used by our laboratory during the analysis on 
this kit are listed below, as well as methods for the calculation of 
absorbencies. 
 
SAMPLE 
EDTA Plasma was used in this thesis for analysis involving this kit, except 
where specified, in chapter 4.2 for the validation of citrate plasma and in 
chapter 4.3, where serum was used for analysis. 
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EQUIPMENT  
 
￿  Thermo Lab systems Multiskan Ascent Microplate reader capable of 
measuring absorbance at 450nm with correction wavelength set at 
540nm or 570nm 
￿  Ascent software package 
￿  Gilson pipettes and pipette tips 
￿  Thermo systems Finnpipette (50µl 300µl) multi channel pipette 
￿  500ml graduated cylinder  
￿  Squeeze bottle  
￿  Electronic timer clock 
￿  Plastic plate sealers supplied with the kit 
 
QUALITY CONTROL 
An internal laboratory quality control (EDTA plasma) was used to make sure 
the assay was running effectively. 
 
CALCULATION 
All calculations were done using the Multiskan Ascent Software Package. 
Analysis was repeated when results fell out with the assay range. 
   
2.4.1.2   Mercodia Adiponectin ELISA Method 
Total adiponectin concentrations in chapter 4.3 were also measured using the 
Mercodia Adiponectin ELISA assay 10 1193 01. See the Mercodia kit insert in 
appendix 3 for assay instructions. Specific equipment and quality controls 
used by our laboratory during the analysis on this kit are listed below, as well 
as methods for the calculation of absorbencies. 
 
SAMPLE 
Serum samples were used for all analysis in this thesis with this kit. 
 
EQUIPMENT 
 
￿  Fisherbrand Whirlimixer 
￿  Thermo Denley minimix plate shaker  Chapter 2: General Methods    63 
￿  Thermo Lab systems Multiskan Ascent microplate reader capable of 
measuring absorbance at 450nm  
￿  Ascent software package 
￿  Gilson pipettes  
￿  Thermo systems Finnpipette (50µl 300µl) multi channel pipette 
￿  1000mL graduated cylinder  
￿  Squeeze bottle  
￿  Electronic timer clock 
￿  Gilson repeater pipette and tips  
￿  Plastic plate sealers supplied with the kit 
 
QUALITY CONTROL 
Mercodia Obesity Control A, B, C/Human is designed to be used as a three 
level control for Mercodia adiponectin ELISA. It is manufactured from Human 
serum. Each Mercodia Obesity Control kit contains 3 vials of lyophilised 
serum, each containing 0.5 mL after reconstitution.  
Ranges:  A = 5.5 – 8.5 ug/mL 
B = 6 – 11 ug/mL 
C = 11 – 19 ug/mL 
Internal quality controls with low, intermediate and high adiponectin 
concentrations should be routinely assayed as unknowns, and results charted 
from day to day.  
An internal laboratory quality control (EDTA plasma) was also used on each 
assay. 
 
CALCULATION 
All calculations were done using the Multiskan Ascent Software Package. 
Analysis was repeated when results fell out with the assay range. 
 
2.4.2  Measurement of High Molecular Weight Adiponectin 
High Molecular Weight adiponectin (and total adiponectin – studies 3.2 and 
4.3) concentrations were measured using the American Laboratory Products 
Company (ALPCO) Diagnostics: Adiponectin (Multimeric) EIA (Catalog Number 
47 ADPH 9755). See the ALPCO Diagnostics kit insert in appendix 3 for assay 
instructions. Specific equipment and quality controls used by our laboratory Chapter 2: General Methods    64 
during the analysis on this kit are listed below, as well as methods for the 
calculation of absorbencies. 
 
SAMPLE 
Serum samples were used for analysis in chapters 3.2 and 4.3. 
EDTA Plasma was used in chapter 5. 
 
EQUIPMENT 
￿  Heating block (temp = 37˚C) 
￿  Fisherbrand whirlimixer 
￿  Versamax microplate reader capable of measuring absorbance at 
492nm with correction wavelength set at 600 700nm 
￿  Softmax Pro computer software package for calculations 
￿  roller mixer (to ensure thorough mixing of pre treatment buffer and 
protease solutions I and II)  
￿  Gilson pipettes and pipette tips  
￿  Thermo systems Finnpipette (50µl 300µl) multi channel pipette 
￿  1000mL graduated cylinder  
￿  Squeeze bottle  
￿  Electronic timer clock 
￿  Gilson Repeater pipette and tips  
￿  Plastic plate sealers supplied with the kit 
 
QUALITY CONTROL 
An internal laboratory quality control (EDTA plasma) was used to make sure 
the assay was running effectively. 
 
CALCULATION 
All calculations were worked out by creating a standard curve using Softmax 
Pro 3.12 computer software. 
 
2.5  Quality Control 
A pooled EDTA plasma sample was used to monitor inter assay quality control 
(QC). Blood from 2 healthy volunteers from the Vascular Biochemistry Chapter 2: General Methods    65 
laboratory was drawn into 9mL EDTA vacutainers (BD Vacutainer Systems: 
Becton, Dickinson and Company). Blood was separated immediately after 
venipuncture by spinning (3000rpm at 4˚C for 10 mins) in the under bench 
centrifuge (Beckman Coulter, GS 6KR) and aliquoting 500 l plasma into apex 
tubes. These tubes were clearly labelled as controls and immediately frozen 
at  80˚C until required.  
 
For ELISA assays, 2 wells at the end of each assay plate were filled with fresh 
QC. The mean of the values from these two aliquots was determined and the 
process repeated over 22 separate runs on R&D systems total adiponectin 
ELISA assays (Chapter 2.4.1.1) and used to calculate out an inter assay 
coefficient of variation (CV).  The CV was calculated out to be 6.73 %. This is 
in line with the published inter assay precision given in the R&D adiponectin 
ELISA standard operating procedure (SOP) (appendix 3) where the CV (%) < 
7.0. This Quality control was also used to calculate out an intra assay CV on 
each run, and this was in each case < 4.5% which is again in line with the 
recommendations given by R&D systems for the ELISA method, where the 
intra assay CV is < 4.7%. 
 
2.6  Statistical Analysis 
For all pre analytical and analytical variables I calculated basic statistics 
(mean, median, CV, standard deviation (SD)) using an Excel spreadsheet.  
 
For all other more complex statistics (excluding the intra class correlation 
coefficients (chapter 3.4)) the website for IFA statistics was used 
(http://www.fon.hum.uva.nl/Service/Statistics.html). Calculations were 
based on those in the paper by Ernst et al, 1985. 
 
To maintain equivalence throughout the thesis, we assumed non normal 
distribution for all pre analytical and analytical variable studies (Chapters 
3+4) and used non parametric tests to carry out statistical evaluation on our 
data in these studies. The pre analytical and analytical studies (chapters 3+4) 
presented in this thesis are not large enough in sample number to assess the 
true skewedness of the distribution. It is acknowledged that a non-parametric Chapter 2: General Methods    66 
test with data from a small sample population with a wide range of values may 
overestimate the significance level. The non-parametric tests may lack 
statistical power with small sample numbers. However, from the majority of 
literature reviewed on adiponectin distribution, the results are mostly highly 
skewed (Sattar et al, 2006; Cavisoglu, 2006) and therefore we have assumed 
non normal distribution. The Wilcoxon matched pairs signed ranks test was 
used in chapters 3.2   3.4 and 4.2   4.3 to determine significance, and the 
Spearman’s rank correlation coefficient was also used in these studies to 
determine whether there was a preservation in the given order between the 
two variables.    
The Wilcoxon matched pairs signed rank test is a non parametric statistical 
hypothesis test for the case of two related samples or repeated measurements 
on a single sample. It can be used as an alternative to the paired Student's t 
test when the population cannot be assumed to be normally distributed. It 
should be used whenever the distributional assumptions that underlie the t 
test cannot be satisfied (median = mean). 
The Spearman’s rank correlation coefficient (r r r r) ) ) ) is a non parametric measure 
of correlation (wikipedia). It assesses if there is a monotonic relation between 
two variables.  
The intra class correlation coefficients presented in the Biological Variability 
chapter 3.4, were calculated out on an Excel spreadsheet according to Fleiss 
(1986). This test is used to determine the optimum number of measurements 
required for an assay to reduce misclassification of individuals (Poorhang, 
MSc, 2005). Dr. Paul Welsh offered his expertise and guidance in the 
calculation of these values.  
 
In the clinical studies chapters 5+6, where sample numbers were much larger, 
distribution was tested for and where appropriate, values were log 
transformed to follow normal distribution.Chapter 3: Pre-Analytical Variables    67 
Chapter III: Methodological Considerations - 
Effects of Pre-Analytical Variables on 
Measurements of Adiponectin  
3.1  Introduction to pre-analytical variables 
 
Many variables can affect the results obtained from analysis of blood samples 
in both the clinic and laboratory environment. Pre analytical variables are 
those variables that may affect sample viability before it is analysed. These 
include season, diet, time of day, stress, and physical activity of the patient, 
as well as encompassing technical aspects of blood collection such as 
venipuncture technique, anticoagulation, processing, and storage of blood 
samples (Welsh, PhD, 2008).  
 
The ELISA method for determination of adiponectin has become an 
increasingly popular and accurate way of measuring levels of adiponectin in 
human blood. It is cost effective and easy to perform, with samples being 
analysed and results being obtained on the same day. However, before one 
can use the results obtained from this method in proposing new thoughts on 
the molecule’s functioning in the body, we have to be sure the results 
obtained are not tainted with potential confounders before analysis. 
Therefore it is essential to understand the steps that must be taken in order 
to maintain a high standard of sample quality.  
 
Due to time constraints it was not possible to investigate all potential 
confounding pre analytical factors, however from the series of studies 
presented in this chapter the aim is to show that adiponectin results 
presented in the clinical/epidemiological study chapters of this thesis can be 
validated accordingly.   Chapter 3: Pre-Analytical Variables                  68
   
This chapter investigates  
￿  Freeze/thaw cycles and the effects this stress may have on measurable 
concentrations of adiponectin in a sample. 
￿  The effect of time taken between venipuncture and separation and the 
temperature a sample may be subjected to during processing and 
before freezing.  
￿  Biological variability in study samples within our laboratory. Chapter 3: Pre-Analytical Variables                  69
   
 
3.2  Effect of Repeated Freeze/Thaw on Adiponectin      
Levels in Human Blood Samples 
3.2.1 Introduction 
Large study cohorts often require several analytes to be measured on their 
limited sample volumes (often only 1 aliquot is available for analysis), and so 
it is not always possible to do all the tests on the first sample defrost. Some 
assays can take 1 2 days to complete and for this reason it may be necessary 
to repeatedly thaw and refreeze the samples on several occasions to allow all 
measurements to be completed. Some peer reviewed studies suggest both 
total adiponectin and HMW adiponectin to be fairly robust, and showed that 
up to five freeze/thaw cycles had no effect on the measurable concentrations 
in plasma (Schraw et al, 2008; Tanita et al, 2008). The robustness of this 
molecule may reflect the reason behind the use of ELISA assays in many 
epidemiological studies; ELISA antibody detection only requires the antigenic 
site to be intact, rather than the marker show biological activity (Welsh, PhD, 
2008). In this study we address the issue of whether this repeated 
freeze/thaw compromises the measureable concentrations of adiponectin in 
the plasma.  
 
3.2.2 Principle 
The aim was to investigate the effect of repeated freeze/thaw on the amount 
of measurable adiponectin in a sample. We also aim to investigate if 
measurable concentrations of adiponectin maintain rank correlation with 
freeze thaw cycles. 
A pilot study was first of all set up examining the effect of 7 freeze/thaw 
cycles on total and HMW adiponectin levels in 5 serum samples from the 
Reykjavik
3 cohort. After this data was analysed, a larger study group of 13 
                                         
 
3 Aims to examine risk factors for out of hospital cardiac arrest. It is a long term, prospective, population based 
cohort study that started in 1967. Methods and results from 1987 to 1996, 137 men and 44 women out of the 8006 
men and 9435 women in the study sustained out of hospital cardiac arrest due to cardiac causes.  
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people was used to study the effects of 5 freeze/thaw cycles on total 
adiponectin levels in plasma samples.  
 
3.2.3 Pilot Study (Reykjavik cohort) 
3.2.3.1 Pilot Study Subjects and Methods 
Blood collection, storage and analysis 
 
The Reykjavik Study, initiated in 1967 as a prospective study of cardiovascular 
disease, has been described elsewhere previously (Danesh et al, 2004). A total 
of 8888 men born between 1907 and 1934 and 9681 women born between 
1908 and 1935 who were residents of Reykjavik, Iceland, and its adjacent 
communities on December 1, 1966 were enrolled in the study. All participants 
had no previous history of myocardial infarction. 9 nurses administered 
questionnaires, made physical measurements, performed spirometry and 
electrocardiography, and collected venous blood samples after an overnight 
fast for the measurement of the erythrocyte sedimentation rate and to 
prepare aliquots of serum, which were stored at  20°C for subsequent 
analysis. A set of 5 samples randomly selected from this cohort were used to 
test the effect of freeze/thaw on the measurable concentrations of 
adiponectin in serum samples. The Reykjavik samples had previously been 
defrosted twice for use in the original Reykjavik study. Five samples from the 
cohort were randomly selected and 250 l from each was aliquoted into a 
separate apex tube. These apex tubes were labelled with sample ID, date and 
control, and subsequently frozen at  80˚C.  
Over the next four consecutive days the original serum sample from the 
cohort was defrosted at room temperature and refrozen. After the final 
defrost on the 5
th day an aliquot from each serum sample was removed into 
an apex tube, labelled with freeze/thaw aliquot and stored at  80˚C for 
analysis. At the end of the pilot study defrosts, and including the previous 
defrosts from the original Reykjavik Study, these samples had undergone a 
total of seven defrosts.  
 
At the time of analysis, the apex tubes were removed from the freezer and 
snap thawed at 37˚C. HMW adiponectin and total adiponectin concentrations Chapter 3: Pre-Analytical Variables                  71
   
were measured on all serum samples using the ALPCO Diagnostics Adiponectin 
ELISA kit (General Methods 2.4.2). The original control samples along with the 
freeze/thaw aliquots from this study were tested on the same plate, thus 
avoiding any inter assay variation. All available data was analysed. 
 
Statistical analysis 
 
Means, Medians, 25
th percentiles and 75
th percentiles (Inter quartile ranges 
(IQR)) were calculated using an Excel spreadsheet. Dr. Paul Welsh advised on 
statistical analysis. The Wilcoxon Matched Pairs Signed Ranks Test was used to 
establish p values and the Spearman’s rank Correlation Test was used to 
establish r values. (Chapter 2, General Methods). The website for IFA 
statistics was used for these tests 
(http://www.fon.hum.uva.nl/Service/Statistics.html). Calculations were 
based on the book by Fleiss in 1986. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter 3: Pre-Analytical Variables                  72
   
 
3.2.3.2 Results  
Results for this pilot study are summarized in tables 3.1 –3.3 
 
Tables 3.1 (Total adiponectin) and 3.2 (HMW adiponectin) summarise the 
effects of freeze/thaw on the 5 pilot study samples from the Reykjavik 
cohort.  Medians, 25
th percentiles and 75
th percentiles are tabulated for both 
the baseline samples/control samples (2 defrosts) as well as for the samples 
after they were subjected to an additional 5 defrosts.  
 
Table 3.3 shows the p values and correlation coefficients obtained from the 
data. Because the sample size was so small it was hard to assess whether the 
data was skewed, so a non normal distribution was assumed and the Wilcoxon 
Matched Pairs Signed Ranks Test was used. P values obtained were non 
significant. The Spearman’s rank correlation was used to calculate r values 
and these show a good correlation between the baseline and the 
freeze/thawed samples. The HMW adiponectin value was borderline 
significant for this test (p<=0.08). 
 
Figure 3.1 (total adiponectin) and 3.2 (HMW adiponectin) show measured 
levels at baseline and after the freeze/thaw cycles. Chapter 3: Pre-Analytical Variables                  73
   
 
Table 3.1: Summary of the Data for Total Adiponectin Concentrations at 
Baseline and After the Freeze/thaw Cycles on the 5 Pilot Study Reykjavik 
Samples. 
 
Time point  Median and IQR ( g/mL) 
of 5 samples 
 
 
Baseline  
 
8.11 
 
IQR 
(8.0 – 11.02) 
 
 
After 7 freeze/thaw cycles 
 
7.78 
 
IQR 
(7.03 – 8.26) 
 
 
Abbreviations for Table 3.1: IQR, Inter quartile range. 
 
 
 
Table 3.2:Summary of the Data for HMW Adiponectin Concentrations at 
Baseline and After the Freeze/thaw Cycles on the 5 pilot Study Reykjavik 
Samples. 
 
Time point  Median and IQR ( g/mL) 
of 5 samples 
 
Baseline  
 
5.53 
 
IQR 
(3.62 - 6.01) 
 
 
 
After 7 freeze/thaw cycles  
 
5.94 
 
IQR 
(4.70 - 6.15) 
 
 
Abbreviations for Table 3.2: IQR, Inter quartile range. 
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Table 3.3: P values and Spearman’s Rank Correlation Coefficients for 
Baseline vs. Freeze/thaw Sample for Both Total and HMW Adiponectin 
Concentrations 
 
  Total adiponectin  HMW adiponectin 
Wilcoxon matched 
pairs signed ranks test 
p = 0.06  p = 0.44 
Spearman’s rank 
correlation coefficient 
 
r = 1, p = 0.02 
 
 
r = 0.9, p = 0.08 
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Figure 3.1: Graph Showing Concentrations of Total 
Adiponectin Measured in the Reykjavik Samples at Baseline 
and After Seven Freeze Thaw Cycles
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Figure 3.2: Graph Showing Concentrations of HMW 
Adiponectin Measured in the Reykjavik Samples at Baseline 
and After Seven Freeze Thaw Cycles
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3.2.3.3 Discussion of pilot study 
There was no significant change in concentrations of adiponectin after 7 
freeze thaw cycles (p = 0.06, total adiponectin; p = 0.44, HMW adiponectin) 
and these samples appear to show very good correlations with the 
control/baseline samples r = 1, total adiponectin; r = 0.9, HMW adiponectin). 
Our results suggest that both total and HMW adiponectin are therefore stable 
for up to seven freeze thaw cycles and these findings corroborate with a 
recent study (Tanita et al, 2008) which found that up to five freeze/thaw 
cycles had no significant influence on the measurable concentrations of HMW 
adiponectin in serum samples.  
 
However these results must be taken in earnest as we must still bear in mind 
that the sample set was small and that larger studies are needed to 
corroborate our result. Small data sets can present a dilemma; it is difficult to 
tell if the data come from a normally distributed population. The non-parametric 
tests are less powerful and the parametric tests are less robust within smaller 
data sets. This fact may attribute to the borderline significant p value that 
was obtained for the HMW adiponectin samples. It is not common practice to 
attribute great belief in a result which has been drawn from a small sample 
set and so I acknowledge that a larger sample set may provide more insight 
into this variable and should be pursued.  
 
Limitations of the study 
 
One of the major limitations with a small study sample set is the fact that one 
cannot determine whether the data is normally distributed and therefore 
statistical analysis has less impact in terms of parametric associations. In 
recent published literature (Sattar et al, 2008; McEntegart, 2007) adiponectin 
results are generally skewed and so for the statistical analysis in this study we 
have assumed a non normal distribution, and used non parametric tests on 
the raw data. Also, in this study, analysis was only carried out on the baseline 
sample and the sample after it had undergone 7 freeze/thaw cycles. 
Concentrations were not measured after each thaw. This was because it was a Chapter 3: Pre-Analytical Variables                  77
   
pilot study and was set up merely to assess if there was a potential for 
samples to deteriorate under this stress.  
 
By defrosting a larger sample set (n = 13) each day for five consecutive days 
and storing an aliquot from each defrost, we can determine better if there is 
any compromise in the concentrations of adiponectin in the sample, and if so, 
at which point the sample starts to deteriorate.  
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3.2.4 Effects of freeze/thaw on measurable concentrations of 
total adiponectin in a larger study group (n=13) 
3.2.4.1 Study subjects and methods  
Blood collection, storage and analysis 
 
13 healthy volunteers, 9 female and 4 male (age 26 – 58 yrs), for this study 
were obtained from the Vascular Biochemistry laboratory at the Glasgow 
Royal Infirmary. Volunteers in the study signed an informed consent form 
(Appendix) giving permission for a trained phlebotomist to take blood. They 
were also informed that their bloods would be used for research purposes and 
stored on the 4
th Floor of the Queen Elizabeth building at the Glasgow Royal 
Infirmary. At the time of bleeding, 1 x 9mL EDTA vacutainer (BD Vacutainer 
Systems: Becton, Dickinson and Company) was taken from these volunteers by 
a trained phlebotomist. The volunteers were not fasted. After venipuncture 
the blood samples were centrifuged (3000rpm, at 4˚C, for 10 mins) in the 
under bench centrifuge (Beckman Coulter, GS 6KR) within 30 mins. The 
separated plasma was aliquoted into blue eppendorf tubes (2 x 1.5mL). These 
tubes were clearly labelled with sample ID, date, time of venipuncture and 
name of study. One of the eppendorfs per volunteer was used as the 
baseline/control sample and stored at  80˚C, while the other was removed 
and snap thawed each day at 37˚C over 5 consecutive days. On each day an 
aliquot was taken from the sample and stored as 1
st thaw, 2
nd thaw, 3
rd thaw, 
4
th thaw and 5
th thaw consecutively. The samples were then kept stored at  
80˚C until analysis could be carried out. On the day of analysis the samples 
were snap thawed at 37˚C. The samples were tested for total adiponectin 
using the R&D Systems ELISA method (General Methods Section 2.4.1.1). All 
samples were measured on the same assay plate in order to avoid inter assay 
variation. Due to financial constraints HMW adiponectin was not tested for on 
this sample set. All available data was analysed.  
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Statistical analysis 
 
Medians, 25
th percentiles and 75
th percentiles were calculated using an Excel 
spreadsheet. Dr. Paul Welsh advised on statistical analysis. The Wilcoxon  
Matched Pairs Signed Ranks Test was used to establish p values and the 
Spearman’s rank Correlation Test was used to establish r  values (Chapter 2, 
General Methods). The website for IFA statistics was used for this test 
(http://www.fon.hum.uva.nl/Service/Statistics.html). Calculations were 
based on the book by Fleiss in 1986. 
 
3.2.4.2 Results 
Results for this study are summarized in tables 3.4 and 3.5. 
 
Table 3.4 shows Medians, 25% IQR’s, and 75% IQR’s for total adiponectin 
concentrations at the 6 time points for all 13 volunteers. As can be seen from 
the table values, the median remains roughly the same throughout the 5 
freeze/thaw cycles.  
 
Table 3.5 summarises p  values and r – values over the 5 freeze/thaw cycles. 
Rank correlation is maintained throughout the 5 cycles and there was no 
significant change between baseline values and those obtained at thaw 1, 3, 4 
and 5. Baseline values compared to thaw 2 values show a significant change, 
however rank order is still maintained on this thaw. 
 
Figure 3.3 graphically shows the total adiponectin median levels over the five 
freeze/thaw cycles.Chapter 3: Pre-Analytical Variables                  80
   
 
Table 3.4: Summary of Data for Total Adiponectin Over the 5 Freeze/thaw 
Cycles. 
 
  Baseline  1
st Thaw  2
nd Thaw  3
rd Thaw  4
th Thaw  5
th Thaw 
 
Adiponectin 
Median and 
IQR for 13 
samples 
( g/mL) 
10.21 
 
(IQR) 
6.57 – 11.84 
 
10.74 
 
(IQR) 
6.73 – 14.40 
 
10.50 
 
(IQR) 
7.72 – 14.04 
 
10.12 
 
(IQR) 
7.30 – 13.05 
 
10.89 
 
(IQR) 
7.38 – 11.89 
 
9.66 
 
(IQR) 
7.41 – 13.39 
 
 
Abbreviations for Table 3.2.4: IQR, Inter quartile range. 
 
 
 
Table 3.5: P values and Spearman’s Rank Correlations for Total 
Adiponectin Measurements Over the 5 Freeze/thaw Cycles. 
 
  Baseline 
vs. 1
st 
Thaw 
Baseline 
vs. 2
nd 
Thaw 
Baseline 
vs. 3
rd 
Thaw 
Baseline 
vs. 4
th 
Thaw 
Baseline 
vs. 5
th 
Thaw 
Wilcoxon 
matched 
pairs 
signed 
ranks test 
 
 
p = 0.50 
 
 
p = 0.01 
 
 
p = 0.95 
 
 
p = 0.45 
 
 
p = 0.96 
Spearman’s 
rank 
correlation 
coefficient 
 
r = 0.89 
 
r = 0.98 
 
r = 0.98 
 
r = 0.95 
 
r = 0.99 
 
 
 
 
 
    
Figure 3.3 Total Adiponectin Median Levels Over the Five 
Freeze/Thaw Cycles
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3.2.4.3 Discussion 
The manufacturers (R&D systems, ALPCO Diagnostics) of the assay kits used in 
this study recommend avoidance of repeated freeze/thaw cycles but if plasma 
samples need to frozen before analysis and thawed again, they should be 
done so speedily after venipuncture and snap thawed at 37˚C to avoid 
denaturation of protein in the sample. Manufacturers do not always specify 
the number of thaws the sample will be stable to on the particular assay. 
 
This study shows that up to five freeze thaw cycles has no significant effect 
on the concentrations of total adiponectin in human plasma. Figure 3.3 
illustrates that median levels of total adiponectin do not change significantly 
over the five freeze thaw cycles. 
 It must be highlighted that the comparison between the baseline samples and 
the samples at the 2
nd thaw showed a significant change (p = 0.01) (table 3.5), 
however the correlation remained strong. Therefore it can be concluded that 
although there may be a statistically significant change in the values at thaw 
2, all samples in the set still maintained rank order and therefore correlate 
accordingly to the values at baseline.  
 
I conclude from the results presented here that total adiponectin is suitable 
to be used in large epidemiological studies where several freeze thaw cycles 
are required before analysis. More data is required using a larger population 
to confirm and further expand on these findings.  
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3.3  Blood Sample Processing 
 
3.3.1 Introduction 
Both in routine and research laboratories, it is not always possible to analyse 
blood samples right away, and sometimes samples can sit on a bench or in a 
fridge for some time before being centrifuged, separated and analysed or 
frozen for storage, especially during busy times. Also, blood samples can be 
sent by post or transferred from doctors or nurses practices’ and these are not 
always delivered the same day. Under good laboratory practice, blood 
samples should be centrifuged for separation within 30 minutes of 
venipuncture, however this is not always possible i.e. when you are not taking 
blood in the vicinity of a laboratory. It is common practice for some tests to 
keep blood bottles refrigerated or on ice if they cannot be centrifuged and 
separated right away. This minimizes breakdown of specific molecules in the 
blood. This section of chapter 3 investigates whether measurable 
concentrations of adiponectin deteriorate in blood samples that have been 
left as whole blood on a bench between 23˚C   25˚C or in a fridge between 4   
8˚C for up to 6 days. This study allowed assessment of the robustness of 
adiponectin to differing modes of sample collection. 
 
3.3.2 Principle 
The aim of this study was to determine if leaving bloods un separated (a) in a 
fridge/cold room (between 4 8˚C) and (b) on a bench at room temperature 
(23˚C   25˚C) for up to 6 days after venipuncture would have an effect on 
measurable concentrations of total adiponectin in EDTA blood samples. Chapter 3: Pre-Analytical Variables                  84
   
 
3.3.3 Study Subjects and Methods 
Blood collection, storage and analysis 
 
13 healthy volunteers, 8 female and 5 male (age 26 – 58 yrs), from the 
Vascular Biochemistry laboratory at the Glasgow Royal Infirmary were 
recruited to take part in the Fridge study and 10 people, 6 female and 4 male 
(age 26 – 58 yrs), from the same laboratory were recruited to take part in the 
Bench study (3 people were unable to be bled for all 6 tubes). Volunteers in 
the study signed an informed consent form (Appendix 5) giving permission for 
a trained phlebotomist to take blood. They were also informed that their 
bloods would be used for research purposes and stored on the 4
th Floor of the 
Queen Elizabeth building at the Glasgow Royal Infirmary. On the day of 
venipuncture six 9mL EDTA vacutainers (BD Vacutainer Systems: Becton, 
Dickinson and Company) were collected from each volunteer. Not all of the 
volunteers were fasted. All samples were labelled with the sample ID, time 
and date of venipuncture, the study name (either Bench or Fridge study), and 
the time point (e.g. baseline, 2 days, 6 days). The cold room in our laboratory 
was kept between 4˚C  8˚C for the duration of this study and the bench 
laboratory temperature ranged between 23˚C   25˚C. Chapter 3: Pre-Analytical Variables                  85
   
 
Figure 3.4: Flow Diagram Showing the Processing of Blood for the Fridge and 
Bench Studies. 
 
 
 
 
Volunteer x 
(n=13)  
Venipuncture at 
baseline 
Six EDTA vacutainers 
Two vacutainers 
centrifuged 
immediately Plasma 
separated and 
aliquoted for Fridge 
and Bench baseline 
samples  
Stored at  80˚C 
Two vacutainers 
stored in the fridge in 
racks between 4 8˚C 
(to be used in Fridge 
study). One tube 
Centrifuged, 
separated, aliquoted 
and stored at  80˚C 
after two days and the 
other after six days 
 
Two vacutainers 
stored on the bench 
in racks between 
23˚C 25˚C (to be used 
in the Bench study). 
One tube Centrifuged, 
separated, aliquoted 
and stored at  80˚C 
after two days and the 
other after six days 
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For each volunteer where possible two of the samples were stored in the 
refrigerator in a safe place between 4 8˚C, two of the samples were stored on 
the bench at room temperature (23˚C   25˚C) and the other two tubes of 
EDTA blood were spun and the plasma separated immediately after 
venipuncture (3000rpm at 4˚C for 10 mins) in the under bench centrifuge 
(Beckman Coulter, GS 6KR). The plasma was immediately aliquoted into 
eppendorf tubes (red eppendorfs for the bench study and green eppendorfs 
for the fridge study) (Figure 3.3). These plasma samples were labelled Bench 
study baseline and Fridge study baseline respectively and stored in a  80˚C 
freezer. Two days after venipuncture another two EDTA blood tubes (one 
from the fridge and the other from the bench) for each volunteer were 
centrifuged and the plasma was aliquoted into labelled eppendorfs (volunteer 
ID, appropriate study name, 2 day sample) and stored alongside the baseline 
plasma samples in the  80˚C freezer. Finally six days after venipuncture, the 
last EDTA blood tubes from each volunteer (1 from the fridge and the other 
from the bench top) were centrifuged and aliquoted into labelled eppendorfs 
(volunteer ID, study name, 6 day sample) to be stored alongside the other two 
samples in the  80˚C freezer. All three samples per person in each study were 
tested for total adiponectin concentrations using an R&D Systems Adiponectin 
ELISA kit (General Methods Section 2.4.1.1). All available data was analysed. 
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Statistical Analysis 
 
Medians, 25
th percentiles and 75
th percentiles were calculated using an Excel 
spreadsheet. Dr. Paul Welsh advised on calculating out P  values and 
correlation coefficients. The Wilcoxon Matched Pairs Signed Ranks Test 
(Chapter 2) was used to establish p values and the Spearman’s rank 
Correlation Test (Chapter 2) was used to establish r  values. The website for 
IFA statistics was used for these tests 
(http://www.fon.hum.uva.nl/Service/Statistics.html). Calculations were 
based on the book by Fleiss in 1986. 
 
3.3.4 Results 
Results from this study are summarised in tables 3.6 – 3.9 
 
Table 3.6 shows medians, and IQR’s for the data obtained during the Fridge 
(between 4 8˚C) and Bench (25˚C) studies.  
 
Table 3.7 summarises statistical analysis from the Fridge study where samples 
were left un separated as whole blood for up to 6 days at 7˚C in a cold room 
before being processed. Comparisons between the baseline samples and those 
blood samples that were processed after being left for 2 days (48hrs) and 6 
days (144hrs) in the fridge show no significant change in measurable 
concentrations of total adiponectin (p= 0.54 and p=1 respectively). There 
exists a significant correlation (r = 0.87, p < 0.0001 (48hrs); r = 0.91, p < 
0.0001 (144hrs)) between the baseline sample values and the values obtained 
from samples that were left un spun as whole blood for 2 days and 6 days in 
the fridge.  
 
Table 3.8 summarises statistical analysis from the Bench study where samples 
were left un separated as whole blood for up to 6 days on the bench top 
between 23˚C 25˚C before being processed. Comparisons between the 
baseline samples and those blood samples that were processed after being 
left for 2 days (48hrs) and 6 days (144hrs) on the bench top show no Chapter 3: Pre-Analytical Variables                  88
   
significant change  in concentrations of total adiponectin (p=0.77 for both 
time points). The 48 hour and 144 hour samples show a good correlation to 
the baseline samples (r = 0.95, p < 0.0001 for both time points). 
 
Table 3.9 illustrates that there was no significant difference in measurable 
concentrations of total adiponectin in EDTA blood samples when left between 
4 8˚C or at 25˚C and this trend was carried through for both 2 day old 
samples as well as those processed after 6 days (p<=1, 2 day samples; p<= 
0.16, 6 day samples). Results obtained from samples left on the bench top at 
23˚C 25˚C correlate well with results from samples left in the fridge between 
4 8˚C at both time points (r = 0.90, 48hr samples; r = 0.92, 144hr samples, 
p<=0.0008). 
 
Figure 3.5 shows total adiponectin values in each subject at each time point 
(baseline, 48 hours and 144 hours) from the Fridge and Bench studies. 
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Table 3.6: Blood Sample Processing Results for Total Adiponectin 
Means and SD’s for all subjects  
 
  Median ( g/mL) 
 
Baseline (0hr) 
 
9.92 
IQR 
(5.93-12.98) 
 
Fridge 2 days after venipuncture 
(48hr at fridge temp.) 
 
9.77 
IQR 
(7.82-11.04) 
 
Fridge 6 days after venipuncture 
(144hr at fridge temp.) 
 
9.41 
IQR 
(6.22-12.05) 
 
Bench 2 days after venipuncture 
(48hr at bench temp.) 
 
8.75 
IQR  
(5.01- 11.86) 
 
Bench 6 days after venipuncture 
(144hr at bench temp.) 
 
8.60 
IQR 
(4.18-11.03) 
 
 
Abbreviations for table 3.6: IQR, Inter quartile range.Chapter 3: Pre-Analytical Variables                  90
   
 
 
Table 3.7: Summary of Data From the Fridge Study Where Blood Samples 
Were Left Between 4 8˚C for 2 and 6 Days Un separated as Whole Blood 
 
  Baseline vs. 2days after 
venipuncture 
Baseline vs. 6days after 
venipuncture  
Wilcoxon matched 
pairs signed ranks test 
 
p = 0.54 
 
 
p = 0.99 
 
Spearman’s rank 
correlation coefficient  
 
r = 0.87, p < 0.0001 
 
 
r= 0.91, p < 0.0001 
 
 
 
 
Table 3.8: Summary of Data From the Bench Study Where Blood Samples 
Were Left at Room Temperature (23˚C   25˚C) for 2 Days and 6 Days Un 
separated as Whole Blood 
 
  Baseline vs. 2days after 
venipuncture 
Baseline vs. 6days after 
venipuncture  
Wilcoxon matched 
pairs signed ranks test 
 
p = 0.77 
 
 
p = 0.77 
 
Spearman’s rank 
correlation coefficient  
 
r= 0.95, p < 0.0001  
 
 
r= 0.95, p < 0.0001  
 
 
 
 
Table  3.9:  Comparison  Between  Data  From  the  Bench  Study  With  Data 
From the Fridge Study 
 
  Bench vs. Fridge (2 
days after 
venipuncture) 
Bench vs. Fridge (6 
days after 
venipuncture) 
Wilcoxon matched 
pairs signed ranks test 
 
p = 0.99 
 
 
p = 0.16 
 
Spearman’s rank 
correlation coefficient 
 
 r= 0.90, p < 0.0001 
 
 
r= 0.92, p < 0.0001 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 Blood Sample Processing
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3.3.5 Discussion 
Our findings show that blood samples left un spun as whole blood in the fridge 
between 4 8˚C and on the bench at 23˚C  25˚C for up to 6 days are still 
viable for total adiponectin analysis and show no deterioration in this variable 
(table 3.7 and 3.8).  
 
Importantly, when the Bench Study values were compared with the Fridge 
Study values for each time point (table 3.9), there was no significant change 
in the values and a good significant correlation between the data sets was 
obtained.  
 
The results presented here found that measurable concentrations of total 
adiponectin were not significantly different in those specimens analysed after 
48 hours or 144 hours compared with those that were processed immediately 
(p = 0.99) (table 3.9). These findings are in line with those reported by 
Pischon et al in 2003, where their findings report no significant change in 
adiponectin levels in 6 male and 6 female EDTA plasma samples when 
processed up to 36 hours after venipuncture (gender adjusted).  
 The findings here also extend to show that temperature did not seem to have 
an effect on measurable concentrations of adiponectin in these un separated 
blood samples for up to 6 days.  
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3.4  Biological Variability 
3.4.1 Introduction 
Measurements of laboratory analytes for individuals are subject to many 
sources
 of variation. These include biological variation, pre analytical
 
variation (specimen collection), analytical variation (bias
 and imprecision), 
and post analytical variation (reporting of
 results). Biological variation, the 
natural fluctuation of body fluid constituents around the homeostatic setting 
point, has two components: within and between subject variation (Ricos et al, 
2000). These components of biological
 variation are used to set analytical 
quality specifications
 for bias and imprecision, evaluate serial changes in 
individual
 analytes, and assess the clinical utility of population based
 
reference intervals (Lacher et al, 2005).
 Concentrations of a molecule in the 
blood can vary over the time of day, between seasons, can depend on 
whether the sample is fasted or non fasted or can vary over a period much 
longer than a day depending on the activity of the subject. Sometimes 
variation in circulating concentrations of molecules can be caused by 
predictable external factors. These include eating patterns, activity and 
seasonal weather changes, thus allowing prediction of biological variation at a 
population level (Welsh, PhD, 2008). However it is those less predictable 
fluctuations that may be of more use in epidemiological studies, because they 
may provide insight into the usefulness of the molecule to predict disease. 
These include response to clinical infection, medication or as a response to 
rises in any other risk markers of disease. It is important to take biological 
variation into account when looking at risk associations in study cohorts. The 
same blood sample for each volunteer should be used to analyse all risk 
markers that can be measured using that type of sample. This will rule out 
potential fluctuating concentrations of variables in the blood that may 
confound the results if measured using different aliquots from the same 
subject.  
 
In 1985, Ernst et al conducted a study involving 15 males and 10 females with 
a mean age of 23 ± 2. This study aimed to investigate intra person variability 
over time. Blood was taken from the subjects on 4 separate occasions at Chapter 3: Pre-Analytical Variables                  94
   
intervals of 7± 2 days. They assayed samples for plasma viscosity, hematocrit, 
red blood cell aggregation, red cell filterability and leukocyte count. After 
analysis they used the mean of the CVs and methodological CVs to calculate 
out the biological CV using the formula listed in methods below. Their results 
state that biological variation tends to be larger than methodological 
variation. 
 
There is limited literature pertaining to the biological variation of adiponectin 
over time. In 2003, Pischon et al published a short technical brief on the 
stability of adiponectin in plasma samples and it’s within person variation 
over one year. The pilot study to test for the 1 year reproducibility of 
adiponectin employed 300 randomly selected men from the previously 
mentioned (Chapter 1) Health Professional Follow up Study (HPFS) (Pischon et 
al, 2004). They included additional samples to assess the intra assay variation 
and found a CV of 20% (n=2). They adjusted their results for BMI, and found no 
significant difference (p=0.09) in adiponectin concentrations taken 1 year 
apart, but showed a high degree of reproducibility (intra class correlation 
coefficient, 0.84, 95% Confidence Interval, 0.65 0.94). Therefore, they 
concluded by suggesting that a single measurement of adiponectin may be 
sufficient for risk assessment in epidemiological studies.  
 
In a recently reported biological variation investigation, HDL C was reported 
to have a dilution regression ration of 0.71 (The Emerging Risk Factors 
Collaboration, 2009). Since adiponectin has known associations with HDL C, it 
is important to investigate whether the concentrations of this molecule 
fluctuate significantly.   
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3.4.2 Principle 
The aim of this study was to investigate biological variation of total 
adiponectin by assessing whether total adiponectin levels vary significantly in 
an individual over the period of 6 weeks. This will allow us to determine if a 
single measurement of total adiponectin is sufficient for use in 
epidemiological studies. 
 
3.4.3 Study Subjects and Methods 
Blood collection, storage and analysis 
 
9 volunteers, 8 women and 1 male (26 – 58 yrs), from the Vascular 
Biochemistry laboratory at the Glasgow Royal Infirmary were recruited for this 
study. Participants in the study signed an informed consent form (Appendix 5) 
giving permission for a trained phlebotomist to take blood. They were also 
informed that their bloods would be used for research purposes and stored on 
the 4
th Floor of the Queen Elizabeth building at the Glasgow Royal Infirmary. 
None of the volunteers were smokers. One 9mL EDTA vacutainer (BD 
Vacutainer Systems: Becton, Dickinson and Company) was taken off each 
volunteer at the same time, on the same day each week, for six consecutive 
weeks. Volunteers were in the same fed state each week. Fasted samples are 
demarcated with an asterisk in table 3.12 below. After venipuncture the 
blood samples were centrifuged (3000rpm, 4˚C, 10 mins.) within 30 min. in an 
under bench centrifuge (Beckman Coulter, GS 6KR). Plasma was separated 
and aliquoted into eppendorf tubes (2 x 1.5mL), using plastic pastettes. The 
eppendorf tubes were clearly labelled with sample ID, name of study and 
week, date and time of venipuncture. The plasma was then stored in the  
80˚C freezer until analysis could be carried out. On the day of analysis all 
samples were snap thawed at 37˚C, and all six samples per person were 
assayed on the same ELISA plate, to minimise inter assay variation of results. 
Samples were analysed on the first defrost using the R&D Systems ELISA 
method (General Methods section 2.4.1.1). All available data was analysed.  
 Chapter 3: Pre-Analytical Variables                  96
   
Statistical analysis 
 
Medians, SDs and CVs were calculated using an Excel spreadsheet.  
 
The laboratory intra assay variability (table 3.10) was quantified by running 
pooled EDTA plasma (from healthy volunteers) on an R&D systems ELISA assay 
(General Methods section 2.4.1.1). Three dilutions from the same plasma 
sample were prepared according to the R&D ELISA SOP and run 8 times on the 
same assay, thereby yielding 24 results in all. The means, standard deviations 
(SD’s) and CVs from each dilution are calculated and tabulated below. The 
mean of the CVs was calculated using excel and used as the intra assay CV in 
this study. 
 
Laboratory inter assay variability (table 3.11) was also quantified. As 
previously explained in chapter 2, this was done by running the same EDTA 
pooled plasma mentioned above, on 22 separate R&D systems total 
adiponectin ELISA assays (General Methods section 2.4.1.1) in duplicate. 
Means were calculated for each assay and then the mean of these means and 
standard deviations were used to calculate out a CV. As expected the inter 
assay CV was higher than the intra assay CV. 
 
Total within person variation (Total CV) is the combined effect of biological 
CV and methodological CV (intra assay CV), the latter being a constant value. 
Biological CV is therefore calculated using the following equation: 
 
Biological CV =         Total CV Methodological CV 
                             1 Total CV 
 
              (Ersnt et al, 1985) 
 
(Refer to appendix 2 for full calculation) Chapter 3: Pre-Analytical Variables                  97
   
 
Dr. Paul Welsh advised on statistical analysis. The Spearman’s rank correlation 
test (Chapter 2, General Methods) was used to compare the concentrations of 
adiponectin taken at baseline to those taken in week 3, and then again 
comparing the baseline concentrations with those from week 6 ( Table 3.14). 
Subject EM was unable to complete the study and so comparisons for 
baseline/week 6 use data from only 8 samples for calculation purposes. The 
website for IFA statistics was used for these tests 
(http://www.fon.hum.uva.nl/Service/Statistics.html). Calculations were 
based on those in the paper by Ernst et al, 1985. 
 
The intra class correlation coefficients (Chapter 2, General Methods) were 
calculated out according to the book on “the design and analysis of clinical 
experiments” by Fleiss, 1986, using an excel spreadsheet. I received guidance 
from Dr. Paul Welsh when performing these tests. 
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Table 3.10: Laboratory Intra Assay Variability 
 
Sample  n  Mean ( g/mL)  SD  CV (%) 
A  8  14.50  0.65  4.50 
B  8  15.56  0.44  2.85 
C  8  17.06  0.83  4.86 
 
Abbreviations for Table 3.10: SD, Standard deviation; CV, coefficient of 
variation. 
 
For the calculation of biological CV, using the equation on the previous page, 
the mean of these CVs was used as the methodological CV. 
This was calculated on an excel spreadsheet as 4.07 %. 
See appendix for full calculation. 
 
 
Table 3.11. Laboratory Inter Assay Variability 
 
  n  mean  SD  CV (%) 
Adiponectin 
( g/mL) 
 
22 
 
 
15.64 
 
 
1.05 
 
 
6.73 
 
 
Abbreviations for Table 3.11: SD, Standard deviation; CV, coefficient of 
variation. 
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3.4.4 Results 
The effects of short term biological variation on adiponectin concentrations in 
plasma are summarised in Tables 3.12   3.15 
Blood samples were taken from 9 healthy volunteers and there were 50 time 
points in total. Subjects DB and EM were unable to give all 6 time points. All 
available data was analysed.  
 
Table 3.12 shows the medians, 25
th percentiles and 75
th percentiles from six 
weeks of results in all 9 volunteers.  
 
Table 3.13 shows the total variability in the 9 volunteers that took part in the 
study. Total CV comprises both a methodological CV and biological CV 
component and these have been calculated out accordingly using the formula 
above and tabulated.  As expected the biological CV was greater than the 
methodological CV, and the mean of intra person means falls within the 
normal range adiponectin concentration value for healthy individuals (0.5 30 
ug/mL) (Magkos et al, 2007). 
 
As we can see from the Spearman’s Rank Correlation coefficients reported in 
table 3.14, total adiponectin concentrations correlate with one another 
throughout the six weeks.  
 
Table 3.15 summarises the intra class correlation coefficient and 95% 
confidence intervals for reliability measurements. The intra class correlation 
coefficient is (0.99, 95% CI: 0.98 – 1.00). 
 
Figure 3.6 shows changes in adiponectin concentrations in all subjects over 
six weeks. 
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Table 3.12: Intra Person Medians (and IQR) of Weekly Measurements of 
Adiponectin. Results Obtained from 50 Observations From 9 People 
(Subjects DB and EM Were Unable to Give all 6 Time Points. 
 
  Median ( g/mL) 
DB*  13.28 
IQR (13.20    13.63) 
PW*  9.93 
IQR (8.84   11.52) 
LC  15.45 
IQR (14.74   17.21) 
MC  9.11 
IQR (8.69   9.95) 
KU  6.64 
IQR (5.84  7.06) 
PS*  1.10 
IQR (1.05   1.07) 
EM  11.59 
IQR (10.96 12.06) 
FC  10.70 
IQR (10.18 11.11) 
GS  5.78 
IQR (5.39 6.12) 
 
Abbreviations for Table 3.12: CV, coefficient of variation; IQR, Inter quartile 
range. Chapter 3: Pre-Analytical Variables                  101
   
 
 
Table 3.13: Total CV and the Relative Proportions That are Methodological 
(Intra Assay) or Biological in Origin.  
Results obtained from 50 observations from 9 people (subjects DB and EM 
were unable to give all 6 time points; refer to appendix for full table of 
results).  
 
Measured Protein  Mean 
of 
intra 
person 
means  
Mean 
of 
intra 
person 
SD’s 
Mean 
of 
intra 
person 
CV’s 
(%) 
Methodological 
CV % 
Biological 
CV % 
 
Adiponectin( g/mL) 
 
9.37 
 
1.21 
 
12.90 
 
4.07 
 
10.14 
 
Abbreviations for Table 3.13: SD, Standard deviation; CV, coefficient of 
variation. 
 
 
 
 
Table 3.14: Spearman’s Rank Correlations From the Comparison of 
Adiponectin Concentrations at Week 1 With Week 3 and Week 1 with Week 
6. 
 
Data Compared  Spearman’s rank correlation 
coefficient 
Baseline with week 3  r= 0.78, p <= 0.02 
Baseline with week 6  r= 0.85, p <= 0.01 
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Table 3.15: Intra Class Correlation Coefficients For Reliability 
Measurements in Short Term Variation. 
 
  Intra class 
correlation 
coefficient   
(95% CI) 
n required 
measurements 
for 75% 
reliability nrep 
(95% CI) 
n required 
measurements 
for 90% 
reliability nrep 
(95% CI) 
Adiponectin  0.99 (0.98 – 1.00)  1 (1 1)  1 (1 1) 
 
Abbreviations for Table 3.15: CI, Confidence Interval; nrep, number of 
required repeat measurements.  
 
 
 
 
 
 
          
Figure 3.6: Changes in Total Adiponectin Concentrations in 
Each Subject over Six Weeks
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3.4.5 Discussion 
It is important to consider the background biological variation in prospective 
studies. A single assessment of a biochemical indicator may be prone to short 
term variation and can lead to under estimation of risk association (Pischon et 
al, 2003). The danger of misclassifying an individual into a particular risk 
category, be it high, intermediate or low, increases with a decrease in 
reproducibility of a marker, therefore damagingly impacting on the usefulness 
of the marker as a clinical tool (Welsh, PhD, 2008).  
 
In this study the intra assay CV (4.07%), is in line with that given by industrial 
kit parameters (2.5   4.7%, R&D systems ELISA; <=3.0, Mercodia and 5.4%, 
ALPCO Diagnostics ELISA). Although, the mean intra person CV was relatively 
high (12.9%), the biological component of this was fairly low (10.14%) as 
compared to some of the inflammatory cytokines (55.7%, CRP and 50.1%, IL 6) 
(Welsh, PhD, 2008), suggesting adiponectin is fairly stable in healthy 
volunteers. Interestingly, taking into account the known positive correlations 
adiponectin has with HDL cholesterol, a meta analysis of 30 studies published 
from 1970 1992 yielded estimates of biological CV of 7.4% for HDL cholesterol 
(Smith et al, 1993). Therefore our findings from this small study are broadly 
consistent with known percentages of variability in established risk markers 
(e.g. HDL C) that display robust correlations with adiponectin. 
 
The good correlations that this study reports between baseline and week 3 (r 
= 0.78) and between baseline and week 6 (r = 0.85) suggests that intra 
individual adiponectin concentrations are fairly stable over short term periods 
(up to 6 weeks) (table 3.14). Also, the intra class correlation coefficient 
(0.99, 95% CI: 0.98 – 1.00) (table 3.15) in this study shows that total 
adiponectin has a high degree of reproducibility and these findings, that a 
single measurement of adiponectin concentration is sufficient for risk 
assessment in epidemiological studies. These findings are in line with those 
from the 2003 study by Pischon et al.  
Figure 3.5 shows no linear trend between mean adiponectin concentrations 
and CV. Therefore CV appears to be independent of the plasma level of 
adiponectin. Larger studies would give a more accurate depiction of this Chapter 3: Pre-Analytical Variables                  105
   
relationship, but at face value, these data are reassuring as they suggest the 
adiponectin assay performs well across a range of values. 
 
Limitations of the study 
 
There were a few limitations to the study that merit discussion. The 50 
samples analysed were not all in the same fed or fasted state. Only 3 of the 
volunteers were in a fasted state when the bloods were taken each week. 
However the state was consistent for each subject throughout the 6 weeks 
and from recent literature, it seems adiponectin levels do not alter 
postprandially (Caixas et al, 2006).  
 
This study was not sufficiently large enough to stratify by sex, age and 
lifestyle factors. All, except two, women were pre menopausal, and all 
individuals, as far as we can judge, led healthy lifestyles. Of note, the males 
had reduced levels of circulating adiponectin. Of course variation exists due 
to other external factors, for example genetic or other unknown metabolic or 
hormonal factors. However, it may not be possible to explain much more of 
the variation in adiponectin concentrations because of biological variation, as 
the mechanism for rises in adiponectin concentrations still requires further 
investigation. As it stands presently, adiponectin shows random pulsatility in 
its secretion (Punthakee et al, 2006). Other factors affecting the 
reproducibility of adiponectin should be considered, these include long term 
storage, freeze/thaw cycles and temperature during assay. Although, our 
prior studies in this thesis suggest adiponectin is in fact quite stable to many 
such considerations. 
 
Also, due to time restraints we were unable to carry on the work for a longer 
period of time. We suggest that additional studies be carried out with larger 
volunteer numbers over a longer study time period and with all volunteers in 
the same fed state.  
 
It may also be interesting to look at biological variability of other forms of 
adiponectin, particularly HMW adiponectin as it is thought to be the more 
biologically active form of the molecule.Chapter 4: Analytical Variables    106 
Chapter IV: 
Methodological 
Considerations - Effects 
of Analytical Variables 
on Measurements of 
Adiponectin  
 
4.1 Introduction to Analytical Variables 
 
Analytical variables refer to problems or differences that may arise with 
performance of a test in the laboratory. The term ‘analytical variable’ refers to 
everything that affects a measurement: the method, the equipment, the 
reagents, the analyst, the laboratory environments, etc. Analytical variability 
can be reduced by adopting a stringent quality assurance procedure and by 
working to good laboratory practice (GLP) standards.  
 
The first study in this chapter investigates compatibility of commercial ELISA 
kits available on the present market for the measurement of total 
adiponectin.  It is important that the variability between commercial kits be 
considered when making comparisons between epidemiological studies, 
because if results obtained for total adiponectin are measured on different 
kits and are not comparable, then assumptions drawn from comparisons of the 
two data sets cannot be validated.  
 
The second study in this chapter aims to validate the use of citrated plasma 
samples for the R&D Systems adiponectin ELISA kit. At present only EDTA 
plasma, serum and cell culture supernates have been validated for use on this 
kit. Sometimes a study may only have one type of aliquot obtainable from 
each volunteer/patient and it may be necessary to do all available tests on 
this sample if re bleeding is not an option. This validation may add further 
scope for total adiponectin analysis when using this kit. 
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4.2  Analysing Citrated Samples for Total Adiponectin 
Using R&D ELISA Methodology 
 
4.2.1  Introduction 
Compounds that do not allow blood to clot are called anticoagulants. The 
most common of these include EDTA, Heparin and Citrate. Most clinical 
laboratory tests are performed using blood collected in EDTA or serum (Green 
et al, 2008). Situations may arise where blood has been drawn from a patient 
and preserved with only one type of anticoagulant and so all tests need to be 
performed on this sample, unless the patient is available for re bleeding. All 
current ELISA assays recommend the use of human serum, EDTA plasma, or Li 
Hep plasma for HMW adiponectin. In addition serum, plasma or cell culture 
supernates are recommended for total adiponectin analysis. It clearly states 
in the user guide for these assays that citrated plasma has not yet been 
validated for use in analysis.  
 
Citrate is usually used for coagulation tests, as well as in blood transfusion 
bags. It gets rid of the calcium, but not as strongly as EDTA (wikipedia). It can 
be in the form of sodium citrate or Acid Citrate Dextrose Solution (ACD). 
Occasionally our laboratory receives only citrated plasma samples for a study. 
We generally like to measure as many variables on a sample as possible to 
gain a better understanding of disease and the associations between 
molecules in the pathogenicity of these various diseases, in particular CVD 
and Diabetes.  
 
It is for this reason that this study aims to validate the use of citrated plasma 
samples in the total adiponectin ELISA assay. There is limited literature on 
this and so validation may prove to be a novel method for adiponectin 
analysis. 
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4.2.2  Principle 
The aim of this study was to validate samples that have been preserved with 
citrate anticoagulant for use in a total adiponectin R&D systems ELISA assay 
(general methods chapter 2.4.1.1). We had a cohort from the Postman study
4 
in which samples had both an EDTA and a citrate aliquot for each volunteer. 
We assayed 109 EDTA plasma samples and the same 109 volunteers’ citrated 
plasma samples on an R&D systems ELISA assay and compared the results to 
see if there was a significant difference in values between the separate 
anticoagulant factors and whether the results rendered from the two sample 
types correlated. 
 
4.2.3  Study Subjects and Methods 
Blood collection, storage and analysis 
 
The following participant recruitment has been previously described 
elsewhere (Chastin et al, 2009). Participants for the study were postal 
workers, recruited from offices in Glasgow, UK. Postal workers within Glasgow 
were informed of the study via work e mail, and participants volunteered to 
take part in the study. Postal workers were selected because there were clear 
distinctions in required activity levels at work between occupational 
categories. In this study, participants were either delivery postal workers who 
walked their delivery route (active workers) or office based postal workers 
(sedentary workers). These categories were used to allow a comparison 
between individuals with typically active and sedentary employment types. 
Participants were non smokers aged between 20 and 60 years, had been 
working for at least 3 months prior to the study, and were not on any 
medication for chronic heart disease, diabetes, hypertension or 
hypercholesterolemia. 
                                         
 
4 Study looking at postal workers in the Glasgow area, UK. Postal workers have clear distinctions in required activity 
levels at work: desk/office job vs. postal delivery worker. This study allows comparison between individuals with 
active and sedentary employment and aims to look at how lifestyle affects CVD risk factors, diabetes, obesity and 
general well being. 
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Written informed consent was obtained from all participants. The study was 
approved by the School of Health and Social Care, Glasgow Caledonian 
University ethics committee, and was performed in accordance with the 
ethical standards laid down in the 1964 Declaration of Helsinki. 
 
I obtained consent from the Principle investigator of the Postman study (Dr. 
William Tigbe) to include my findings from his samples in my study.  
Blood was drawn, by a trained medical practitioner, into two EDTA 
vacutainers (BD Vacutainer Systems: Becton, Dickinson and Company) and a 
citrate vacutainer (BD Vacutainer Systems: Becton, Dickinson and Company). 
These were placed on ice at the post office where blood was taken and 
immediately transported back to the Vascular Biochemistry laboratory for 
separation. The bloods were processed within 2 hours of venipuncture, where 
they were spun (3000rpm at 4˚C for 10 min.) in an under bench centrifuge 
(Beckman Coulter, GS 6KR) and the plasma separated with pastettes and 
aliquoted into eppendorf tubes (Blue for citrate and red for EDTA). The 
eppendorfs were clearly labelled with sample ID, date and time of 
venipuncture and placed in a  80˚C freezer until analysis could be carried out 
on them. On the day of analysis samples were removed from the freezer in 
batches of 78, snap thawed at 37˚C and assayed on a R&D systems ELISA assay 
(general methods, chapter 2.4.1.1). Since each plate can only accommodate 
78 study samples and 2 controls, two plates were used to fit the 109 EDTA 
samples on for analysis and two separate plates were used to fit the 109 
citrate samples on. Total adiponectin and citrate were measured on the first 
defrost of these samples. All available data was analysed.  
 
Statistical Analysis 
 
Medians and CVs were calculated using an Excel spreadsheet. Dr. Paul Welsh 
advised on calculating out p  values and correlation coefficients. The 
Wilcoxon Matched Pairs Signed Ranks Test (Chapter 2) was used to establish 
p values and the Spearman’s rank Correlation Test (Chapter 2) was used to 
establish r  values. The website for IFA statistics was used for these tests 
(http://www.fon.hum.uva.nl/Service/Statistics.html). Calculations were 
based on the book by Fleiss in 1986. Chapter 4: Analytical Variables    110 
 
4.2.4  Results 
Table 4.1 summarises medians, 25
th percentiles and 75
th percentiles (IQR’s) 
for both the citrate and EDTA sample types in all 109 volunteers. 
 
Table 4.2 shows results from statistical analysis on the two sample types. 
There seems to be a significant change in concentrations of total adiponectin 
when measured on citrate samples compared to concentrations obtained from 
the EDTA samples (p< 0.001) (both measured using the R&D systems ELISA 
method). The Spearman’s Rank Correlation Coefficient between these two 
data sets was 0.96 and highly significant (p< 0.001).  
 
Figure 4.1 illustrates a Bland Altman plot of the mean of EDTA and Citrate 
log transformed values vs. the difference between the log transformed values 
of adiponectin concentrations from each sample type (Citrate and EDTA) using 
the R&D systems ELISA assay (general methods, chapter 2.4.1.1). Citrate 
values seem to be consistently lower than the EDTA values obtained using this 
assay. Chapter 4: Analytical Variables    111 
 
 
Table 4.1 Summary of Data for EDTA Plasma and Citrate Plasma Measured 
on an R&D ELISA Assay for the Determination of Human Total Adiponectin 
 
Type of sample  Median ( g/mL) 
 
 
EDTA Plasma 
 
6.10 
 
IQR 
(4.89 - 9.47) 
 
 
 
Citrate Plasma 
 
 
5.34 
 
IQR 
(3.84 - 8.48) 
 
Abbreviations for table 4.1: IQR, Inter quartile range. 
 
 
 
 
Table 4.2 Summary of Data from the Comparison of Total Adiponectin 
Results Obtained from Citrate Plasma and EDTA Plasma 
 
Statistical test  Citrate Plasma vs. EDTA Plasma 
 
Wilcoxon matched pairs signed ranks 
test 
 
p < 0.0001 
 
 
Spearman’s rank correlation 
coefficient 
 
r = 0.96, p < 0.0001 
 
 
                      
 
Figure 4.1: Illustrating Bland Altman Plot of Mean of EDTA and Citrate Logged Total Adiponectin Values vs. the Difference between the 
EDTA and Citrate Logged Adiponectin Values 
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4.2.5 Discussion 
It is imperative to know the viability of sample types for different laboratory 
tests. In most cases the sample types that have been validated for the assay 
will be stated in the assay SOP. Although EDTA plasma is the most widely used 
sample type for most laboratory analysis, it may be necessary in some 
instances for another type of sample to be used. As is the case with large 
epidemiological studies, and if finance permits, a researcher would aim to 
test as many variables on that one sample to get a wider knowledge on the 
interactions of molecules in a disease/healthy state. 
 
In this study one aim was to validate Citrate plasma samples for use on an 
R&D total adiponectin ELISA assay. From statistical analysis of the data (table 
4.2), we can see that although there may be a significant difference in the 
actual concentrations of total adiponectin between the citrate and the EDTA 
samples (p< 0.0001), the highly significant correlation coefficient of 0.96 
demonstrates that the samples maintain rank order between the two sample 
types. Figure 4.1 shows a Bland Altman plot of the mean of the EDTA and 
citrate samples vs. the difference between the two measurable 
concentrations from each sample type. The plot shows that on average the 
Citrate samples rendered lower total adiponectin values than the EDTA 
samples did (those values below the red line) (Figure 4.1). Looking at absolute 
concentrations, the total adiponectin concentrations measured on citrate 
samples were about ~1 g/mL lower than those concentrations obtained from 
the EDTA samples. This discrepancy is almost certainly due to the dilution 
effects, since citrated tubes contain 0.5mls of fluid to which 4.5mls of blood 
is added.  
 
In conclusion, EDTA samples produce higher total adiponectin values than the 
citrated samples do when using this ELISA assay, but the correlation is still 
very good. Therefore citrated plasma samples could be validated for use. It’s 
not an issue that the citrate values are slightly lower, as long as they are 
consistently lower within a study. However, it must be noted that the same 
type of sample should be used throughout the duration of a study; study Chapter 4: Analytical Variables    114 
   
results would not be comparable if one half of the cohort was measured on 
EDTA plasma and the other half of a cohort on citrate plasma. 
 
We suggest that larger studies are needed to corroborate this result.Chapter 4: Analytical Variables    115 
   
                 
4.3  Comparison of Total Adiponectin Measurement by 
Three Different Commercially Available ELISA Kits 
 
4.3.1 Introduction 
As previously mentioned, adiponectin automatically self binds to form larger 
structures and there are different multimeric forms including LMW trimers, 
MMW hexamers, HMW oligomeric structures and finally globular adiponectin. 
The varying forms have altered biological activity and therefore may also have 
separate functions. 
 
A human adiponectin ELISA is designed to measure the concentration of 
molecules in human plasma/serum. Until recently ELISA’s for the 
determination of adiponectin allowed only for the measurement of total 
adiponectin on samples. However, interest in adiponectin multimerisation and 
the regulation of its isoform distribution was fuelled by several studies 
indicating that most of the biological activity of adiponectin was attributed to 
the HMW form rather than to the LMW and MMW complexes. It became 
necessary for there to be a method capable of measuring all of the multimeric 
complexes. A handful of methods have been used for the isolation and 
measurement of HMW adiponectin, based on velocity gradient centrifugation 
(Scherer et al, 1995), gel filtration chromatography (Tsao et al, 2002) and 
polyacrylamide gel electrophoresis (Waki et al, 2003). However more 
recently, novel ELISA’s have been developed to measure not only the total 
adiponectin concentrations in a given sample, but also the varying oligomeric 
forms of this molecule.  
 
Prior to the introduction of this novel kit from ALPCO diagnostics (General 
Methods section 2.4.2), only total adiponectin measurement was available, 
the most popular of these being the R&D Systems adiponectin ELISA (general 
Methods 2.4.1.1).The R&D kit makes use of antibodies raised against human 
adiponectin and so allows for the direct determination of plasma levels of the 
protein. The ALPCO kit still employs the same sandwich enzyme technique 
typical of the ELISA assay, but also allows for the measurement of all of the 
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into its varying molecular weights. Also reported in this study is the 
performance of the Mercodia ELISA assay for the determination of total 
adiponectin concentrations in human samples (general methods 2.4.1.2). It is 
a new addition to this line of ELISA assays. It employs the same sandwich 
enzyme technique as the other two assays in which two monoclonal antibodies 
are directed against separate antigenic determinants on the adiponectin 
molecule, but like the R&D systems product only allows for the determination 
of total adiponectin concentrations.  
 
It has become common practice (if finance allows) for researchers in this field 
to measure both the total and HMW species and to express these as a ratio to 
one another. The advantage of the ALPCO ELISA method is the ability to 
measure total concentrations of the molecule as well as the various forms of 
adiponectin by utilising the same standards and the same protocol. Therefore 
one is able to determine a more realistic analysis of the adiponectin 
distribution in a given sample. This is a more reliable way of determination as 
opposed to using one method for measuring total adiponectin and another for 
HMW adiponectin measurement. This is important as some studies (Magkos et 
al, 1995; Bluher et al, 2007) report differences in the ability of commercially 
available assays for total adiponectin. This is likely due to the variable 
specificity of the different antibodies used for each adiponectin isoform 
(Magkos et al, 1995). However, at times it may be the case that total 
adiponectin has already been measured on a data set in the past, with a kit, 
that at the time, only allowed for the measurement of total adiponectin, and 
as it has become common practice to now include a ratio incorporating the 
HMW adiponectin measurement, a different kit now needs to be employed for 
this purpose. Therefore we need to determine whether these two kits 
correlate to one another. 
 
By comparing the total adiponectin concentrations obtained from the ALPCO 
and Mercodia kits to the adiponectin concentrations rendered from the R&D 
Systems kit, we could examine whether the kits correlated and whether the 
three kits produced similar results.  
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4.3.2   Principle 
We had a sample set from the EarlyBird
5 Cohort (Murphy et al, 2008) which 
had previously been analysed for total adiponectin in the original cohort, 
using the R&D Systems ELISA method. When the ALPCO and Mercodia kits 
became available we measured total adiponectin on the same sample set 
using these kits. 
 
We measured total adiponectin on a subset of 75 serum samples from the 
EarlyBird Cohort, using the ALPCO diagnostics ELISA method and the Mercodia 
adiponectin ELISA method. Results from these tests were then compared to 
the previously determined total adiponectin concentrations measured using 
the R&D Systems ELISA method. 
 
 
 
                                         
 
5 The EarlyBird study involves 300 schoolchildren and their families. It is a 12-year diabetes study to find which factors 
in childhood lead to the development of diabetes later in life. The study gathered unique data on the factors that 
underlie the early development of diabetes/heart disease (physical activity, energy expenditure, dietary choices and 
body composition), the influence of those factors on the insulin resistance that underlies disease and the impact of 
insulin resistance on the markers of disease as children grow and mature (http://www.earlybirddiabetes.org/ Chapter 4: Analytical Variables    118 
 
4.3.3  Study Subjects and Methods 
Blood collection, storage and analysis 
 
The collection of these samples started in 2000 and continued right up 
until 2008. The method for blood collection has been documented 
elsewhere (Murphy et al, 2008). In short, children attended a hospital 
based
 outpatient facility at 0800–0900 after an overnight fast
 of at least 10 
hours. Venous blood was collected into Vacutainer Tubes (BD Vacutainer 
Systems: Becton, Dickinson and Company) and delivered to the
 laboratory 
within 2 hours. After centrifugation (1500g for 10 min),
 samples for the 
original Earlybird cohort study were either analysed straight away or 
stored at  20˚C. When samples were transferred to our laboratory they 
were stored at  80˚C.  
For the purpose of this study and due to financial constraints (high price of 
ALPCO kits), eighty samples were chosen randomly from the Earlybird 
cohort study.  This set consisted of samples from 40 volunteers each with 
two visits. However not all volunteers were able to attend both visits, 
therefore there were 75 samples available for analysis. Total adiponectin 
concentrations were measured using the: 
 
1.  R&D systems ELISA method (General Methods 2.4.1.1)  
2.  Mercodia adiponectin ELISA method (General Methods 2.4.1.2)  
3.  ALPCO diagnostics ELISA method (General Methods section 2.4.2).  
 
All available data was analysed. 
 Chapter 4: Analytical Variables    119 
   
Statistical analysis 
 
Medians were calculated using an Excel spreadsheet. Dr. Paul Welsh 
advised on calculating out P  values and correlation coefficients. The 
Wilcoxon Matched Pairs Signed Ranks Test (Chapter 2) was used to 
establish p values and the Spearman’s rank Correlation Test (Chapter 2) 
was used to establish r  values. The website for IFA statistics was used for 
these tests (http://www.fon.hum.uva.nl/Service/Statistics.html). 
Calculations were based on the book by Fleiss in 1986. Chapter 4: Analytical Variables    120 
   
4.3.4   Results 
Table 4.3 illustrates medians, 25
th percentiles and 75
th percentiles for 
total adiponectin measurements on the three kits (R&D systems, Mercodia 
and ALPCO Diagnostics). On average the concentrations of total 
adiponectin measured on the ALPCO kit were lower than when measured 
with the other two kits. 
 
Table 4.4 summarises statistical analysis of comparisons between the R&D 
systems ELISA and the ALPCO Diagnostics ELISA. There is a highly 
significant difference between total adiponectin concentrations measured 
in the same set of samples on the R&D kit and those obtained from the 
ALPCO Diagnostics kit (p< 0.0001). The data set rendered a correlation 
coefficient of 0.89 and this was a highly significant correlation (p< 
0.0001). 
 
Table 4.5 summarises statistical analysis of comparisons between the R&D 
systems ELISA and the Mercodia ELISA method. There is a highly significant 
difference between total adiponectin concentrations measured in the 
same set of samples on the R&D kit and those obtained from the Mercodia 
kit (p< 0.0001). The data set rendered a correlation coefficient of 0.83 
and this was a highly significant correlation (p< 0.0001). 
 
Figure 4.2 illustrates a Bland Altman plot of the means of the log 
transformed concentrations measured on the R&D and ALPCO kits vs. the 
difference between the log transformed concentrations rendered from 
each of these kits. There is a suggestion of a slight negative bias such that 
levels are proportionately lower as adiponectin concentrations increase.  
 
Figure 4.3 illustrates a Bland Altman plot of the means of the log 
transformed concentrations measured on the R&D and Mercodia kits vs. Chapter 4: Analytical Variables    121 
   
the difference between the log transformed concentrations rendered from 
each of these kits.  
 
 
 
 
Table 4.3: Summary of Data from Total Adiponectin Concentrations 
Measured on 80 Samples With the R&D Systems ELISA Assay, the ALPCO 
Diagnostics ELISA Assay and the Mercodia ELISA Assay. 
 
 
Abbreviations for table 4.3: IQR, Inter quartile range. 
 
         Median ( g/mL) 
   R&D Systems 
 
          10.48 
          IQR 
            (8.41 13.89) 
 
           
          Alpco Diagnostics 
 
 
 
            7.37 
            IQR 
             (6.27 9.08) 
 
       Mercodia 
 
            9.86 
            IQR 
              (8.17 12.07) 
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Table 4.4: Comparison of Total Adiponectin Measurements Taken 
From the R&D Systems Kit and the ALPCO Diagnostics Kit. 
 
R&D Systems vs. ALPCO 
 
  
Wi    Wilcoxon matched pairs signed 
ranks test 
 
  p< 0.0001 
 
 
        Spearman’s rank correlation 
coefficient 
  r = 0.89, p< 0.0001 
 
 
 
 
Table 4.5: Comparison of Total Adiponectin Measurements Taken 
From the R&D Systems Kit and the Mercodia Kit. 
 
   R&D Systems vs. Mercodia 
 
 
           Wilcoxon matched pairs 
signed ranks test 
 
 p< 0.0001 
 
 
           Spearman’s rank correlation 
coefficient 
  r = 0.83, p< 0.0001 
 
 
              
 
Figure 4.2: Bland Altman Plot Illustrating the Means of the Logged Adiponectin Values from the R&D and ALPCO Kits vs. the Difference 
Between the Logged Adiponectin Values Rendered from Each Kit 
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Figure 4.3: Bland Altman Plot Illustrating the Means of the Logged Adiponectin Values from the R&D and Mercodia Kits vs. the 
Difference between the Logged Adiponectin Values Rendered from Each Kit 
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4.3.5   Discussion  
In order to make comparisons between large epidemiological studies, 
researchers need to be sure that the different commercial kits available 
for analyte measurement are comparable to one another. This study 
tested three commercially available ELISA kits for the determination of 
human adiponectin. Two of the kits (R&D and Mercodia) allow only for 
the measurement of total adiponectin and the third kit (ALPCO 
diagnostics) allows for the determination of all forms of the molecule, by 
use of selective proteases. The performance of the ALPCO and R&D kits 
from this study has been published in the Journal of Clinical 
Endocrinology & Metabolism (Sattar et al, 2008) and presented in 
chapter 5 of this thesis.  
 
In the comparison between all of the kits there are highly significant 
differences in the concentrations of total adiponectin measured. On 
average, the R&D systems kit renders the highest values (8.41 13.89) 
followed closely by the Mercodia kit (8.17 12.07) and the ALPCO 
diagnostics kit (6.27 9.08) giving the lowest values. This may be due, in 
part, to the extremely high sample dilution factor (1:5151) used in the 
ALPCO methodology compared to the R&D (1:100) and the Mercodia 
(1:101) kits. There is more chance for error in the ALPCO methodology 
too, as the dilution requires two dilution steps whereas the other two 
methods described in chapter 2 only require a single dilution step. This 
may also explain the slight negative bias seen in figure 4.2, where at 
higher levels of adiponectin concentrations, the difference in values 
between the kits is proportionately larger. With this noted however, it is 
reassuring to report that the ALPCO and R&D kits were as closely ranked 
(r =0.89) as the R&D and Mercodia kits (r =0.83). The very strong 
correlation coefficient factors suggest that there is a very good 
correlation between all kits, and although there may be differences in Chapter 4: Analytical Variables    126 
   
the absolute concentrations, as long as this difference is consistent, 
comparisons between kits is good. It must be mentioned that Mercodia 
approached our laboratory after reading the journal article on the 
comparisons between the ALPCO diagnostics and R&D systems kits 
(Sattar et al, 2008). Mercodia were keen to validate their new total 
adiponectin ELISA. We agreed to assist and in doing so were given 
permission to publish the results in this thesis. 
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Chapter V - High Molecular Weight 
Adiponectin and Incident Coronary 
Heart Disease: Findings from a 
prospective Case Control Study 
Nested within the British Women’s 
Heart and Health Study. 
5.1  Introduction 
In recent years, literature on the relationship of circulating levels of 
adiponectin to incident vascular events has attracted a lot of attention. 
The adipocyte derived hormone, adiponectin, has apparent anti 
inflammatory (Gervois et al, 2007) and insulin sensitising properties 
(Kadowaki et al, 2006) therefore attracting considerable interest from 
research groups involved with CVD risk markers. Adiponectin has been 
shown to display a negative relationship with BMI, CRP and triglycerides, 
as well as a positive strong relationship with HDL cholesterol (Figure 5.1) 
(Wannamethee et al, 2007). Whilst there is consistent evidence that high 
levels of adiponectin are associated with lower risk for incident diabetes 
(Lindsay et al, 2002; Wannamethee et al, 2007), it remains unclear 
whether high adiponectin levels are associated with lower risk for CHD 
events. One of the first studies to publish results on the relationship of 
adiponectin with CHD noted that high levels of total adiponectin were 
independently associated with lower risk for incident myocardial events 
(Vozarova et al, 2002). However since then other prospective studies 
have not been consistent. Our group showed no significant association of 
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study (BRHS), and in a subsequent meta analysis of 7 prospective studies 
involving a total of 1318 CHD cases; including results from the British 
Women’s Heart and Health Study (BWHHS) (Figure 5.2) (Sattar et al, 
2006). Therefore, at present it is still unclear whether circulating levels 
of adiponectin are related to risk for incident vascular events.  
 
Adiponectin is known to circulate in a number of different multimeric 
forms within our body, including a low, middle and high molecular 
weight species. From recent data, it is thought that the latter HMW 
adiponectin species is the biologically active form of the molecule. HMW 
adiponectin has been shown to be better associated with insulin 
sensitivity than total adiponectin (Hara et al, 2006), be more strongly 
associated with incidence for diabetes (Nakashima et al, 2006), and it is 
also thought that the HMW moiety may be key to the vascular protective 
properties of the molecule, because it has been shown to be strongly 
linked to protection against endothelial cell apoptosis (Kobayashi et al, 
2004). From this evidence, it is possible that the HMW form rather than 
the total adiponectin is more relevant to the risk for incident CHD 
events. Studies of this nature are still lacking. Until recently, the 
measurement of HMW adiponectin on a given sample was costly, complex 
and labour intensive. However, although still expensive, the introduction 
of an ELISA method for determination of separate adiponectin fractions 
has made it easier to measure HMW adiponectin on larger sample sets. 
Due to funding constraints we were not able to measure HMW 
adiponectin on all of the BWHHS samples and so we carried out a nested 
case control study taking baseline samples from women with subsequent 
CVD events and randomly selected control women of a similar age who 
did not suffer a CVD event.  Chapter 5: High Molecular Weight Adiponectin and Incident Coronary Heart Disease    129 
   
 
 
 
Figure 5.1: Graphs Showing the Relationship of Adiponectin with Various 
Parameters in Humans.  
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Abbreviations for figure 5.1: CRP, C reactive protein; HDL C, High 
Density Lipoprotein Cholesterol; HOMA IR, Homeostasis Model 
Assessment; TG, Triglyceride. 
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Figure 5.2: Figure Showing the 7 Prospective Studies of Circulating 
Concentrations of Adiponectin and CHD Risk.  
 
We can see from the graph below the overall total meta analysis shows no association 
between adiponectin levels and risk for CHD, because the confidence interval crosses 1. 
Note that this figure shows CHD risk ratios for those individuals in the top third of 
baseline adiponectin levels versus those in the bottom third. Pischon’s study (HPFUS) 
(the first to report on the associations of adiponectin with CHD) shows a significant 
association between increased levels of adiponectin and myocardial events. As we can 
deduce from the data on this figure, studies since then have not been consistent with 
these findings. In particular, note the BRHS, the largest published study carried out on 
this relationship to date, demonstrates a non significant association. 
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5.2   Principle 
Our aim was to test whether HMW adiponectin was better associated 
with risk for incident vascular events than the previously reported total 
adiponectin from the original BWHHS (Lawlor et al, 2005).   
 
5.3   Study Subjects and Methods 
Blood collection, storage and analysis 
 
The BWHHS is a prospective cohort study of 4,286 women randomly 
selected from 23 British towns between 1999 and 2001 and who were 
aged 60 79 years at baseline (Lawlor et al, 2002). The prospective case 
control study and end point ascertainment nested within this cohort and 
used herein has been previously described (Lawlor et al, 2005). Briefly, 
women with CHD at baseline were excluded, and incident cases of CHD 
were identified through medical records and death registration up to 
January 2004. An incident case was defined as either of (i) death with an 
underlying or contributing cause of CHD (ICD10 codes I20 I25, I51.6); (ii) 
a myocardial infarction (WHO criteria), first diagnosis of angina or 
coronary artery by pass or angioplasty. There were 167 incident cases of 
CHD (101 non fatal and 66 fatal). Two controls were randomly selected, 
within 5 year age groups of the cases, from women without CHD at the 
baseline assessment. The BWHHS has Local  and Multi Centre Research 
Ethics Committee (LREC and MREC) approvals and all participants 
provided written informed consent for their medical records to be 
reviewed. 
 
Baseline blood samples were taken after a minimum six hour fast. HMW 
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Diagnostics) (General methods section 2.4.2). This ELISA has been 
validated against the “gold standard” conventional fractionation, with 
excellent reported correlations (r = 0.94 to 0.97) between methods 
(http://www.alpco.com/pdfs/47/Human%20Multimeric%20Adiponectin%2
0Details.pdf). The intra assay CV was 6%.  Since we had previously 
measured total adiponectin in the same cohort by a different ELISA (R&D 
systems, UK) (General methods section 2.4.1.1), we assayed total 
adiponectin by the ALPCO method in a subset of 80 samples and 
compared this measurement to the results obtained two years previously 
using the R&D ELISA method: a correlation of r = 0.89 between methods 
was noted despite blinded measurements, conducted several months 
apart with different dilutions. These results concur with our findings that 
the R&D and ALPCO kits are well correlated for total adiponectin 
measurement in serum samples (chapter 4.3). Repeated sample freeze 
thaw did not influence HMW adiponectin values (chapter 3.2).  
 
Methods for insulin, glucose, lipid levels and C reactive protein and 
homeostasis model assessment of insulin resistance (HOMA IR) have been 
detailed previously (Lawlor et al, 2002). All blood samples were taken 
between 08.00 and 18.00 with the time of sampling (to nearest minute) 
recorded. Levels of total adiponectin and HMW adiponectin did not vary 
by time of day of sampling (data not shown). 
 
Statistical analysis  
 
Associations of continuous covariables with HMW adiponectin and total 
adiponectin were assessed using Spearman’s rank correlation 
coefficients.  
Correlation coefficients are presented for the entire sample (cases and 
controls combined) as there was no evidence of these associations 
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were assessed using an unpaired t test for continuous variables and chi 
squared test for categorical variables. Multiple logistic regression was 
used to assess the association of HMW adiponectin with CHD with 
adjustment for covariables. For positively skewed variables (HMW 
adiponectin, total adiponectin, CRP, glucose, insulin, HOMA IR scores 
and triglycerides), geometric means and their 95% confidence intervals 
were used. Logged values were used for regression models. HMW 
adiponectin and total adiponectin were entered as continuous variable 
(natural logs) in these regression models. Regression coefficients for 
logged exposure variables are difficult to interpret and for this reason 
the effect estimates were expressed as the risk ratio of CHD for a 
doubling of HMW adiponectin or total adiponectin. Non linear 
associations of quarters of the HMW adiponectin distribution were 
explored first as a series of three indicator variables and then as a 
continuous score and computing a likelihood ratio test comparing these 
two nested models. We repeated our analyses using conditional logistic 
regression and found the same results. All analyses were conducted in 
Stata version 9.0 (StataCorp., Texas). 
 
5.4   Results 
Of the randomly selected samples, one control did not have a baseline 
sample and therefore data was available for 167 cases and 333 controls. 
Table 5.1 shows the correlation of HMW with total adiponectin, giving an 
r = 0.75. Also from table 5.1 we can see both HMW adiponectin and total 
adiponectin were inversely associated with waist to hip ratio, fasting 
insulin, glucose, HOMA IR, CRP and triglyceride levels and positively 
associated with HDL c levels. 
 
The 95% confidence interval levels of HMW adiponectin were not 
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(3.90, 4.47)  g/ml, where p = 0.7. As previously reported by Lawlor et al 
in 2005, cases had a higher fasting insulin, glucose, HOMA IR, LDL c and 
lower HDL c. Triglyceride levels and systolic and diastolic blood pressure 
were similar. However hypertension and smoking were greater and use 
of HRT less at baseline in cases compared with controls. 
 
In a multivariable analysis we found no association between HMW 
adiponectin and incident CHD (Table 5.2). The age adjusted relative risk 
ratio for CHD for a doubling of HMW adiponectin was 0.96 (0.78, 1.18) 
(Table 5.2) and adjustment for any confounders did not alter this (model 
2 and 3, Table 5.2).  
 
Figure 5.3 shows the effect of HMW adiponectin by quarters of its 
distribution and from our examination we found no evidence of any 
linear or non linear associations.  
 
There was also no association of the ratio of HMW adiponectin:total 
adiponectin with CHD risk: age adjusted relative risk per doubling of the 
ratio 1.10 (0.80, 1.50). 
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Table 5.1: Correlation of High Molecular Weight Adiponectin and Total 
Adiponectin with Measures of Adiposity, Insulin, Glucose and Lipid Levels 
in British Women aged 60 79 Years.  
 
Spearman rank correlations
< 0.001 -0.42 < 0.001 -0.34 Triglyceride 
< 0.001 0.44 < 0.001 0.37 HDL-C
< 0.001 -0.20 0.002 -0.17 CRP
< 0.001 -0.38 < 0.001 -0.30 HOMA-IR 
< 0.001 -0.20 0.01 -0.11 Glucose 
< 0.001 -0.41 < 0.001 -0.35 Insulin
< 0.001 -0.32 < 0.001 -0.26 WHR
< 0.001 -0.20 0.008 -0.12 BMI 
< 0.001 0.75 - - HMW
p total adiponectin p HMW adiponectin
 
Abbreviations for Table 5.1: HMW, High Molecular Weight; BMI, Body 
Mass Index; WHR, Waist to hip Ratio; HOMA IR, homeostasis model 
assessment of insulin resistance; CRP, C Reactive Protein, HDL C, High 
Density Lipoprotein C. 
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Table 5.2: Multivariable Associations of High Molecular Weight 
Adiponectin with Incident Cases of Coronary Heart Disease (N=167 cases 
and 333 controls). 
 
 
  
a Model 1: Adjusted for age (continuous in years) 
b Model 2: as model 1 plus adult social class (4 level categorical 
variable entered as a score 1 parameter) smoking (3 level categorical 
variable entered as a score 1 parameter) and physical activity (3 
level categorical variable entered as a score 1 parameter) 
c Model 3: as model 2 plus, waist:hip ratio systolic blood pressure, 
fasting levels of high density lipoprotein, triglyceride (logged), 
glucose (logged), insulin (logged) and CRP (logged) (all continuous 
variable) 
 
 
  Relative risk 
ratio (95% 
confidence 
interval) for a 
doubling of HMW 
adiponectin 
p linear trend  p non linear 
association 
Model 1: age 
adjusted
a 
0.96 
(0.78 1.18) 
 
 
0.71 
 
0.96 
Model 2: 
confounder 
adjusted
b 
 
0.98 
(0.79 1.21) 
 
 
0.85 
 
0.79 
Model 3: 
adjusted for 
confounders 
and potential 
mediators
c 
 
1.01 
(0.81 1.24) 
 
0.89 
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Figure 5.3: Proportion (%) of Women with Incidence Coronary Heart Disease 
(cases) by Quarters of the Distribution of High Molecular Weight Adiponectin. 
 
The first quartile incorporates the bottom quarter of adiponectin values (i.e. those individuals 
having the lowest circulating adiponectin levels). The fourth quartile incorporates those 
women with the highest circulating levels of adiponectin. If there was a significant link 
between protection against CHD and levels of adiponectin, we would expect to see a linear 
relationship with those in the first quartile having a significantly higher incidence of CHD % 
than those in the fourth quartile. There is no evidence of any linear relationship here. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Incident    
CHD %   
Quarters of HMW adiponectin distribution   
1     2     3     4    
15    
20    
25    
30    
35    
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5.5    Discussion 
A journal article on these findings has been published in the Journal of Clinical 
Endocrinology & Metabolism (JCEM) (Sattar et al, 2008) and includes the 
following contributing authors: Sattar N, Watt P, Cherry L, Ebrahim S, Davey 
Smith G, Lawlor DA (included in this thesis in appendix 4). 
 
Our findings go against a clear link between HMW adiponectin and risk of 
incident vascular events. In line with our findings, Halperin et al reported no 
link between %HMW or total adiponectin and a vascular risk surrogate 
(endothelium dependent vasodilation) in offspring of diabetic parents (Halperin 
et al, 2005). More interestingly, recent evidence suggests that higher 
adiponectin levels may actually predict higher risk for CVD mortality in the 
general population (Laughlin et al, 2007). HMW adiponectin predicts higher risk 
of mortality in patients with heart disease (Tsutsamoto et al, 2007), findings 
consistent with the observation by McEntegart et al in which they also reported 
a positive correlation between circulating adiponectin levels and BNP 
(McEntegart et al, 2007). In recent published literature (Kizer et al, 2008), it 
was demonstrated that higher levels of adiponectin predict increased risk of 
first ever CHD in older adults (inclusive of men and women). This latter study 
includes a large number of incident vascular events with good attention to 
potential confounders. These data suggest adiponectin and indeed its fractions 
have a complex relationship with vascular disease.  
 
An editorial by Sattar and Nelson (Sattar et al, 2008) suggests reverse causality 
for the link between higher levels of adiponectin and the higher risk of CVD 
mortality. The editorial puts forward the notion that silent or clinically 
apparent vascular disease could lead to compensatory rises in adiponectin. 
Indeed adiponectin is thought to dampen the early phases of macrophage 
inflammatory responses, acting to inhibit the growth of myelomonocytic 
progenitor cells and decrease the ability of mature macrophages to respond to 
activation (Yokota et al, 2000; Gervois et al, 2007). This inhibited functioning 
of macrophages results in a reduced uptake of oxidised LDL, and this in turn 
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atherosclerosis.  Sattar and Nelson also mention the positive correlation 
adiponectin exhibits with BNP in patients with chronic heart  
failure, as well as those without, and alternately it could be that a rise in BNP 
may link silent ischemia or vascular disease to higher adiponectin levels. In line 
with this McEntegart and colleagues (McEntegart et al, 2007) recently proposed 
the idea that the high levels of adiponectin in those with heart failure or acute 
coronary syndrome may represent a salvage mechanism to improve insulin 
resistance and fatty acid metabolism, thereby attempting to counteract 
metabolic or vascular stress (Sattar et al, 2008).  If this was indeed true, then 
an investigation into the link between adiponectin levels and mortality risks in 
those with chronic vascular disease should be a good indicator of the validity of 
these suggestions. One such study (Dekker et al, 2008) has touched on the 
subject and its findings point to a positive correlation between these two 
parameters. 
 
Finally, although we expected the correlation between HMW adiponectin and 
HOMA IR score to be greater than between total adiponectin and HOMA IR given 
its apparent increased association with insulin sensitivity (Nakashima et al, 
2006; Lawlor et al, 2005), this was not so in our study. Similar results have also 
been observed by other researchers (Retnakaran et al, 2007).  
 
There may be possible limitations to our study that merit discussion. We 
understand that our study cannot be extrapolated to men and other ethnic 
groups and larger studies are needed to corroborate our null result, although 
the adjusted result of 1.01 (0.81, 1.24) for incident CHD events with a doubling 
of HMW adiponectin is close to unity (Sattar et al, 2008). Some may argue that 
using kits from two different suppliers for the measurement of total and HMW 
adiponectin may affect our results. However, although our method for 
determination of HMW adiponectin is fairly new, we believe it to be robust. It 
should be noted that Bluher et al questioned the robustness of this method in 
their report (Bluher et al, 2007). Their study included 60 women who spanned 
glycaemia thresholds and reported no association of total adiponectin by the 
ALPCO method with two other methods for total adiponectin, with their p value 
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no association of either total or HMW adiponectin with fasting insulin levels (r = 
 0.09, and r =  0.04 respectively, both non significant).  Our study, by contrast,  
included 500 women without diabetes, and found the HMW fraction to correlate 
nicely with the total adiponectin (r = 0.75, p<0.001) using different methods 
for determination. Furthermore the total adiponectin measurement using the 
ALPCO kit correlated with the R&D ELISA on a subset of 80 samples (r = 0.89, 
p<0.001), even though the tests were done blinded and two years apart. In 
addition, the HMW fraction correlated with fasting insulin ( 0.35, p<0.001) and 
with other metabolic parameters in the expected fashion (Table 5.1). Other 
groups have used gold standard techniques such as velocity sedimentation 
technique to report similar correlations between total and HMW adiponectin. 
For example Halperin et al (Halperin et al, 2005) reported a correlation of r 
=0.72 between %HMW and total adiponectin. Also, the ALPCO method has been 
validated against more conventional methods for adiponectin fractionation 
including immunoblotting and velocity sedimentation technique, and has been 
shown to perform well. Finally, others (von Eynatten et al, 2007; Hara et al, 
2006) have used larger sized cross sectional studies than that published by 
Bluher and colleagues, to show good performance of kits and a correlation to 
insulin sensitivity and related parameters. Therefore our null findings are 
unlikely to be due to methodological issues, although clearly more work in this 
area is required. 
 
In conclusion, despite evidence to suggest that the HMW form of adiponectin is 
the biologically active form of the molecule, our results go against a significant 
inverse association between HMW adiponectin and incident CHD events. The 
findings from this study do however further support the notion that circulating 
adiponectin has a stronger association with diabetes than with vascular disease. 
Uncertainty still lies with the role adiponectin plays in vascular disease and 
more studies are required to investigate further.  
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Chapter VI - Serial Changes in 
Adiponectin and BNP in ACS Patients: 
Paradoxical Associations with Each Other 
and with Prognosis 
 
6.1 Introduction  
As mentioned previously throughout this thesis, adiponectin has been shown 
to have the unusual property of correlating inversely with markers of 
adiposity. It has also been suggested to possess anti inflammatory properties 
(Ouchi et al, 2007) and in line with this may protect cardiac tissue and 
increase inflammatory dampening thereby limiting the occurrence of 
atherogenesis (Ouchi et al, 2006).  
 
Despite adiponectin’s clear link to lower diabetes risk, its relationship to CHD 
is not clear. An initial study linked low levels of adiponectin to increased risk 
of CHD events in healthy men (Pischon et al, 2004), however a recent meta 
analysis suggested a more modest association with CHD (Sattar et al, 2006). 
Further to this, studies in people with prevalent heart failure or acute 
coronary syndromes show that high plasma levels of adiponectin are 
associated with greater disease severity (Nakamura et al, 2006; McEntegart et 
al, 2007) and with higher risk of adverse outcome (Tsutamoto et al, 2007; 
Kistorp et al, 2005; George et al, 2006; Cavusoglu et al, 2006). These studies 
highlight the complexity of the relationships adiponectin displays with regard 
to health and disease within the body. Circulating adiponectin concentrations 
may represent both a protective or theoretically harmful signal depending on 
the context.  
 
Brain natriuretic peptide (BNP), now known as B type natriuretic peptide (also 
BNP) is a 32 amino acid polypeptide secreted by the ventricles of the heart in 
response to excessive stretching of heart muscle cells (cardiomyocytes). BNP 
was originally identified in porcine brain and thereby got its name, but in 
humans it is found mainly in cardiac ventricles. BNP and its inactive N 
terminal metabolite NT proBNP (released in 1:1 ratio during processing) are 
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with CHF (Clerico et al, 2004).  Baseline NT proBNP and BNP have positive 
correlations with adiponectin in those with prevalent CHF and CAD (Nakamura 
et al, 2006; McEntegart et al, 2007; Tsutamoto et al, 2007; Kistorp et al, 
2005; George et al, 2006; Cavusoglu et al, 2006;  Clerico et al, 2004; von 
Eynatten et al, 2006; Tanaka et al, 2008). In particular the recent Atherogene 
study showed that baseline adiponectin predicted risk of poor outcome in CHF 
independent of conventional risk factors, but not independent of BNP 
(Schnabel et al, 2008). 
 
To further investigate the potential pathological link between BNP and 
adiponectin, we examined in 442 ACS patients the inter relationship of 
circulating adiponectin and BNP both at baseline and at a 7 week follow up 
(338 patients) with adverse outcomes at 10 months to determine whether 
change in either parameter was a better predictor of adverse events than a 
single measurement. Changes in concentrations of adiponectin over time were 
also investigated to see if they correlated with changes in BNP over time. 
 
6.2 Materials and Methods 
6.2.1    Study population 
442 Caucasian patients with the diagnosis of ACS (between August 2004 and 
November 2006) were consecutively recruited at Ninewells Hospital, Dundee. 
Patients were recruited if they presented within 72 hours after the onset of 
ischemic discomfort  and included those diagnosed with (Cnop et al, 2003)  ST 
elevation MI (STEMI); ST elevation >1mm in 2 limb leads or >2mm in leads V1  
V6 or new left bundle branch block, (Lafontan et al, 2006) Non ST segment 
elevation MI (NSTEMI); no ST elevation on ECG despite elevated Troponin T 
>0.01 ug/mL, (Ouchi et al, 2007) Unstable angina; ischaemic chest pain 
lasting more than 30 minutes with no evidence of myocyte necrosis or ST 
elevation. Ethical approval was obtained from the Tayside Committee of 
Medical Research Ethics and all participating subjects gave written, informed 
consent. The research was carried out in accordance with the Declaration of 
Helsinki. During the ACS admission, the patients underwent the following 
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(1) Clinical history and risk factor analysis. 
(2) Evaluation of admission Killip class defined as follow: 
· Killip class I: No clinical signs of heart failure. 
 
· Killip class II: Rales or crackles in the lungs, an S3 gallop, and elevated 
jugular venous pressure. 
· Killip class III: Frank acute pulmonary oedema. 
· Killip class IV: Cardiogenic shock or hypotension (measured as systolic BP 
lower than 90 mmHg), and evidence of peripheral vasoconstriction (oliguria, 
cyanosis or sweating). 
(3) ECG: presence of absence of ST deviation (>1.0 mm). 
(4) Bedside BNP assay. 
(5) Laboratory tests: admission haemoglobin, eGFR using the modification of 
diet in renal disease equation and serum Troponin T level. 
(6) Bedside echocardiography: LV systolic dysfunction (LVSD) defined as LVEF 
<45% (Simpson’s biplane method) and left ventricular hypertrophy (LVH) 
assessment. 
 
6.2.2 Echocardiography 
Transthoracic echocardiography was performed by one trained operator using 
an 
Acuson (Sequia 512) imaging system with a 3V2C transducer. The scan was 
performed with the patient lying in the left lateral position at approximately 
45%. 
 
6.2.3 Left ventricular hypertrophy assessment 
Patients were studied with two dimensional guided M mode echocardiography 
in standard views. All measurements were made according to the American 
Society of Echocardiography (ASE) recommendation at end diastole, taken as 
the onset of QRS complex. The leading edge to leading edge convention was 
used to measure interventricular septal thickness, left ventricular internal 
diameter and left ventricular posterior wall thickness. Measurements were 
made over at least 3 separate cardiac cycles and the average taken. Left 
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0.80 (ASE left ventricular mass) + 0.6 (Devereux et al, 1986) and indexed to 
body surface area to give a left ventricular mass index (LVMI). Left ventricular 
hypertrophy was defined as LVMI greater than 95g/m2 in females and greater 
than 115 g/m2 in males in accordance to ASE guidelines (Lang et al, 2005). 
 
6.2.4 Left ventricular systolic function assessment 
Quantitative assessment of LV systolic function was made using the modified 
biplane Simpson’s method to calculate a LVEF. Three measurements from 
successive cardiac cycles were made in the two chamber and four chamber 
views. LVSD was defined as an LVEF < 45%. 
 
6.2.5 Blood sample collection and analysis 
Samples were collected by venipucture into EDTA vacutainer tubes or serum 
clot accelerators. One EDTA vacutainer of blood sample was kept at room 
temperature and analysed for BNP within 4 hours of the draw time. Whole 
blood was analysed with the triage BNP assay (Biosite, USA) as reported 
previously (Morrison et al, 2002). The inter assay CV was 8.8% at 71.3 pg/mL 
and 11.6% at 4088 pg/mL. The detection limit was 5 pg/mL. An 
electrochemilumninescent immunoassay approved for quantitative 
measurement of Troponin T was provided by Roche Diagnostics and run on 
Roche Modular E170 unit. At 0.06 ug/L a CV of 10% is achievable and the 
detection limit was 0.01 ug/L. Blood samples for adiponectin or other non 
routine analyte measurement were spun at 2000g for 15 min and the serum or 
plasma layers were aliquoted within 4 hours, snap frozen, and stored at –
80°C. Total plasma adiponectin was analysed using a commercially available 
kit (R&D systems, Oxon, UK). The inter assay CV for the adiponectin assay was 
less than 8%. The same methods were used for samples at follow up 
measurements. 
 
6.2.6 Follow-up Measurements 
7 weeks after baseline admission, an attempt was made to re examine 
patients with a full ECG, trans thoracic echocardiography to assess LVEF, and 
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samples (average time of follow up 52 ± 17 days). Of the 442 baseline patients 
(of whom 90 experienced adverse outcomes (detailed below) by 10 months), 
433 were still alive, and 338 consented to continuing participation in the 
study at 7 weeks (of whom 51 experienced adverse outcome by 10 months). In 
relating BNP and adiponectin levels to risk of outcome we used all 442 
baseline patients for whom measurements were obtained, and the 338 patient 
samples available to us from the 7 week measurement 
 
6.2.7 End points 
The end point of death from any cause, readmission with ACS or admission 
with congestive heart failure (CHF) was evaluated at 10 months (265.79 ± 
80.31 days). Information on end points was collected from telephone 
interviews with patients or patient relatives, hospital database and patients 
case notes. The definition of readmission with ACS is as described above. 
Congestive heart failure was defined as hospitalization for a clinical syndrome 
involving at least 2 of the following: paroxysmal nocturnal dyspnoea, 
orthopnoea, elevated jugular venous pressure, pulmonary crackles, third 
heart sound and cardiomegaly or pulmonary oedema on chest X Ray. These 
clinical signs and symptoms must have represented a clear change from the 
normal clinical status, requiring intravenous diuretics, inotropic support or 
vasodilator therapy. 
 
Statistical analysis 
Continuous variables are summarized as median and 25th and 75th percentile. 
For discrete variables, absolute and relative frequencies per category are 
given. Variables were logarithmically transformed to obtain normal 
distributions, with tertiles of adiponectin generated. Inter group differences 
were assessed by chi squared test or analysis of variance. Spearman 
correlation coefficients are reported. The association of adiponectin with 
adverse outcome was examined in different binary logistic regression models, 
first a univariate model, then in a model adjusting for classical risk factors, a 
third model additionally adjusted for baseline BNP and a fourth model for 7 
week BNP. Goodness of fit of the models was tested by Hosmer Lemeshow. 
Statistical significance was determined at p <0.05. 
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6.3  Results 
6.3.1    Baseline characteristics  
In the complete patient group the median BNP level at baseline was 154 
pg/ml (inter quartile range [IQR] 53 336), and the median baseline 
adiponectin level was 6.76mg/ml (IQR 4.16  10.82). With continuous analyses, 
the baseline correlation between BNP and adiponectin was r = 0.32, 
(p<0.001).  
 
Table 6.1 illustrates baseline characteristics of the patients according to 
tertiles of adiponectin concentration. As expected, age increased across 
tertiles of adiponectin (p for trend <0.001). Some other major cardiovascular 
risk factors showed inverse associations with adiponectin including proportion 
of male gender (p<0.001), BMI (p<0.001), and total cholesterol (p=0.07) while 
HDL cholesterol increased across tertiles (p<0.001). Blood pressure, presence 
of hypertension, diabetes, or smoking habit showed no significant association 
with adiponectin levels. Haemoglobin levels and kidney function (eGFR) 
decreased across adiponectin tertiles (p<0.001). Among clinical measures, left 
ventricle ejection fraction (p<0.001) decreased, and sub optimal prognosis 
according to Killip class increased (p=0.004) with increasing adiponectin.  
 
6.3.2 Changes in adiponectin and BNP from baseline to 7 
weeks  
 
The median BNP level at 7 weeks was lower compared to baseline at 94pg/ml 
(IQR 36 198) and the median adiponectin level was 5.49mg/ml (IQR 3.48 
8.99). With continuous analyses the 7 week correlation between BNP and 
adiponectin was r =0.33, (p<0.001). Overall change in adiponectin and BNP 
levels between baseline and 7 week follow up for the whole patient group are 
shown in Fig 6.1 a and b respectively. As can be seen from these figures both 
the change in adiponectin and BNP were near normally distributed, with the 
former being slightly left skewed and the latter right skewed (skewedness 
statistic  1.22 and 1.80 respectively). For both biomarkers there was a spread 
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week interval. Figure 6.2 (with both markers log transformed to normality) 
demonstrates a significant correlation between changes in BNP versus change 
in adiponectin. Indeed the correlation (r =0.39, p<0.001) was at least as 
strong as the baseline and 7 week correlations between parameters noted 
above.  
6.3.3 Associations of baseline adiponectin and BNP with 
adverse outcome 
In unadjusted models, baseline adiponectin showed a borderline significant 
association with outcome: OR 2.06 (95% CI 0.92 4.63) p=0.08 (Table 6.2a). 
Adjusting for classical risk factors (including clinical parameters) attenuated 
the association (OR 1.63 [0.54 – 4.93]). Subsequent adjustments for BNP levels 
attenuated the association of baseline adiponectin with risk to near unity. As 
seen in Table 6.2b however, BNP remained significantly associated with poor 
outcome in every adjustment model, even after adjusting for baseline 
adiponectin (OR 3.26 [1.54 – 6.91]).  
 
6.3.4 Associations of 7 week adiponectin and BNP with adverse 
outcome 
Among those who survived the first 7 weeks following ACS and who consented 
to further study, the association between 7 week adiponectin and risk of poor 
outcome was not considerably different to the association seen at baseline, 
and none was significant, perhaps due to reduced power with fewer 
observations (Table 6.2a).In contrast, the association of 7 week BNP with risk 
of poor outcome was substantially stronger, and was independent of classical 
risk factors, and independent of 7 week adiponectin (OR 6.84 [2.54 – 18.45]) 
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6.3.5 Associations of change in adiponectin and BNP with 
adverse outcome 
Change in adiponectin (Table 6.2a), appeared somewhat more strongly linked 
to risk for adverse outcome than either baseline or 7 week adiponectin. For 
change in adiponectin the unadjusted OR was 5.42 (2.78 – 10.55), and 
attenuated to OR 3.99 (1.79 – 8.92) with adjustment for classical markers, and 
to OR 3.17 (1.29 – 7.78) with additional adjustment for change in BNP. Change 
in BNP was not itself independently associated with adverse outcome in the 
latter model, suggesting change in adiponectin was the stronger marker. Since 
change in adiponectin and 7 week BNP appeared to have the strongest 
independent associations with outcome, we included both markers in same 
multivariable model to test whether 7 week BNP could explain the association 
of change in adiponectin with prognosis. After doing this, change in 
adiponectin was no longer associated with risk for adverse outcome (OR 1.13 
[0.27 – 4.92]), but 7 week BNP measurement remained significantly associated 
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Table 6.1: Association between admission adiponectin levels (divided into 
thirds) and baseline characteristics of ACS patients (n=442 with 
adiponectin measurement) 
 
 
Abbreviations for table 6.1: ACS, Acute coronary syndrome; eGFR, estimated glomerular 
filtration rate; LBBB, left bundle branch block; LV, left ventricular.    
Data presented are the number (%) of patients or median and 25
th/75
th IQR for continuous 
variables. p values represent trends across adiponectin third
Characteristic 
 
 
Bottom third 0.48 
4.85 g/mL (n=147) 
Middle third 4.86 8.94 
85 g/mL (n=148) 
Top third 8.95 35.40 
85 g/mL (n=147) 
p value* 
 
Age  60 (12)  66 (11)  69 (11)  <0.001 
Sex Male/Female n (%)  125/22 (85/15)  98/50 (66/44)  77/70 (52/48)  <0.001 
Systolic blood pressure 
(mmHg) 
130 (115 150)  131 (118 – 150) 
  128 (110 – 147)  0.23 
Diastolic blood pressure 
(mmHg) 
70 (63 81)  72 (65 – 82) 
  70 (60 – 80)  0.18 
Total cholesterol 
(mmol/L) 
5.12 (4.19 6.08)  4.81 (3.94 –5.95)  4.52 (3.85–5.62)  0.07 
HDL cholesterol (mmol/L)  1.15 (0.99 1.33)  1.32 (1.11–1.47)  1.50 (1.2 –1.82)  <0.001 
BMI (kg/m
2)  28.0(26.0 31.0)  26.0 (24. – 29.0)  25.0 (22.0–29.0)  <0.001 
Smoking n (%)        Never  46 (31)  57 (38)  52 (35) 
                         Past  41 (28)  44 (30)  52 (35)   
Present  60 (41)  47 (32)  43 (30)  0.21 
Haemoglobin (g/dl)  15.0 (14.1  15.8)  14.1 (12.7–14.9)  13.3 (12.1– 14.4)  <0.001 
eGFR 
(mL/min/1.73m
2) 
70 (59 78)  66 (52– 75)  61 (51– 73)  <0.001 
Troponin T (ng/mL)  0.27 (0.01 1.86)  0.36 (0.06 1.47)  0.31 (0.07 1.43)  0.98 
Non ST elevation ACS (%)  69  75  75  0.353 
Type 2 Diabetes n (%)  21 (14)  23 (16)  16 (11)  0.48 
History of hypertension(%)  61 (41)  71 (48)  74 (50)  0.29 
ST deviation on ECG n (%)  73 (50)  68 (46)  71 (48)  0.81 
LBBB on ECG n (%)  4 (2.7)  5 (3.4)  7 (4.8)  0.63 
LV ejection fraction (%)  57 (49 63)  55 (45 – 62)  52 (39 – 61)  0.001 
LV Hypertrophy (%)  84 (66)  81 (71)  74 (67)  0.680 
Killip class 2,3 or 4 n (%)  8 (5)  13 (9)  25 (17)  0.004 
 
BNP (pg/mL) 
81 (39 216)  152 (44–343)  239 (114 489)  <0.001      
   
Table 6.2a Association (Odds ratio) between baseline adiponectin, 7 week adiponectin, and change in adiponectin and collective 
adverse outcomes of mortality, heart failure or acute coronary syndrome (n=51) within 10 months of index acute coronary syndrome 
events. 
                                                                                                                                                                                   
                                                 Adiponectin  Measurement 
                                                                                                                                                              
Adjustment model  Baseline adiponectin  7 week adiponectin  Change in adiponectin 
Unadjusted  2.06 (0.92 4.63)  2.19 (0.79 – 6.08)  5.42 (2.78 – 10.55) 
Classical risk factors  1.63 (0.54 – 4.93)  1.31 (0.33 – 5.27)  3.99 (1.79 – 8.92) 
Classical risk factors + 
baseline BNP 
1.18 (0.38 – 3.64)       
Classical risk factors + 7 week 
BNP 
   0.74 (0.17 – 3.28)    
Classical risk factors and 
change in BNP 
      3.17 (1.29 – 7.78) 
 
ORs for adiponectin and BNP are for 1 log unit increase in the patient population. 
Classical risk factors = Age, sex, BMI, pre existing hypertension, pre existing diabetes mellitus, Killip class 2,3 or 4, ST deviation, left bundle branch block, log troponin 
on admission, CKD stages 3, 4 or 5, left ventricular systolic dysfunction, smoking status, haemoglobin on admission, total and HDL cholesterol concentrations.      
   
Table 6.2b Association (Odds ratio) between baseline BNP, 7 week BNP, and change in BNP and collective adverse 
outcomes of mortality, heart failure or acute coronary syndrome (n=51) within 10 months of index acute coronary 
syndrome events. 
 
                                                                                                                                                             
                                                              BNP Measurement 
                                                                                                                                                
Adjustment model  Baseline BNP  7 week BNP  Change in BNP 
Unadjusted  4.29 (2.59 – 7.11)  6.73 (3.33 – 13.60)  2.33 (1.13 – 4.82) 
Classical risk factors  2.83 (1.35 – 5.92)  6.54 (2.49 – 17.21)  3.07 (1.25 – 7.53) 
 
Classical risk factors + baseline 
adiponectin 
3.26 (1.54 – 6.91)       
Classical risk factors + 7 week 
adiponectin 
   6.84 (2.54 – 18.45)    
 
  ORs for adiponectin and BNP are for 1 log unit increase in the patient population. 
Classical risk factors = Age, sex, BMI, pre existing hypertension, pre existing diabetes mellitus, Killip class 2,3 or 4, ST deviation, left bundle branch 
block, log troponin on admission, CKD stages 3, 4 or 5, left ventricular systolic dysfunction, smoking status haemoglobin on admission, total and HDL 
cholesterol concentrations.                          152
   
Figure titles  
 
Figure 6.1 (a&b): Dot plots of the untransformed overall change in 
adiponectin and BNP between baseline observations and follow up 
observations 7 weeks later in the patient group. 
 
Figure 6.2: Correlation of change from baseline at 7 weeks follow up for 
adiponectin and B type natriuretic peptide. Delta values represent (log 
follow up value – log baseline value) for both adiponectin and BNP. 
 
                          
Figure 6.1a 
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Figure 6.1b 
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6.4  Discussion 
A journal article has been published on these findings in Clinical Science 
London (Ang et al, 2009) and includes the following contributing authors: Ang 
DS, Welsh P, Watt P, Nelson SM, Struthers A, Sattar N (included in this thesis 
in appendix 4).   
 
To our knowledge, this is the first study to date to examine the association of 
circulating adiponectin and BNP with risk of poor outcome in a group of ACS 
patients where serial measurements have been made. Importantly, an 
increase in adiponectin 7 weeks after admission was more strongly associated 
with risk of adverse outcome than a single measure at either time point – in 
other words, if adiponectin levels increased, adverse event risk was greater, 
whereas the absolute levels of adiponectin at either time point were less 
important. In contrast, 7 week BNP measurement was more strongly 
associated with risk, superior to both baseline and change in BNP 
measurements. In terms of independent risk prediction, the strongest marker 
of risk of adverse events was 7 week BNP, which was associated with risk 
independently of change in adiponectin. Finally, although the patterns of risk 
associations of these markers are different, these data allow us to show that 
following index admission for ACS, BNP and adiponectin associate with each 
other at baseline, at follow up, and that change in both markers also 
correlate (r =0.39, p<0.001). Our finding of a positive correlation between 
baseline circulating BNP and adiponectin, although apparently paradoxical on 
the basis of presumed functions of adiponectin, was an expected result based 
on previous findings in similar patient groups (Nakamura et al, 2006; 
McEntegart et al, 2007; Tsutamoto et al, 2007; Kistorp et al, 2005; George et 
al, 2006; Cavusoglu et al, 2006; von Eynatten et al, 2006; Tanaka et al, 2008; 
Schnabel et al, 2008). Our finding that 7 week BNP is more strongly related to 
adverse outcome than BNP at admission is in agreement with a recent study in 
157 CHF patients, where discharge BNP was shown to be strongly associated 
with poor outcome (Cournot et al, 2008). We do not propose that our results 
definitively answer the question of whether circulating BNP and adiponectin 
are or are not clinically useful in prognosis of ACS. Rather, our results may 
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CHF, or death following an index ACS event. Our results are suggestive of an 
interesting and potentially important pathphysiological pathway which links 
an increase in adiponectin to adverse prognosis in a manner not independent 
of BNP. Although an observational study cannot imply a causal link, it is 
interesting to speculate on the potential relationship of adiponectin and BNP 
following ACS. We found that absolute levels of BNP at 7 weeks were the 
strongest predictor of prognosis. This makes sense, since levels of BNP 
following the settling of acute phase response and/or changes in clinical 
therapies after an event will better represent long term cardiac /vascular 
status, and therefore subsequent risk. In contrast to BNP, increasing levels of 
adiponectin following index ACS admittance were potentially more strongly 
related to risk than baseline or 7 week adiponectin, and yet this relationship 
was partially dependant on 7 week BNP in multivariable models. This may be 
suggestive of some association between progressive disease severity and 
changes in adiponectin (as measured by follow up BNP). The Atherogene 
investigators have very recently shown that the relationship of baseline 
adiponectin with risk of death or non fatal MI in a group of coronary artery 
disease patients is confounded by associations with BNP (Schnabel et al, 
2008). Our observations now extend this observation to show that the two 
parameters also change in parallel post ACS, such that the risk associations of 
adiponectin with risk are dependant on BNP. This provides evidence that 
there may be a direct or indirect link between high post ACS BNP and a rise in 
adiponectin in those at greatest risk of poor outcome. If there is a link 
between the two parameters, are there any clues to mechanisms? Natriuretic 
peptides may directly stimulate higher adiponectin levels since a novel 
lipolytic and potential lipid mobilising effect of natriuretic peptides has been 
identified (Sengenes et al, 2000). These actions appear to be mediated by 
specific adipocyte membrane receptors, which operate via a cGMP dependent 
pathway and they may indirectly stimulate adiponectin production (Sengenes 
et al, 2000). Furthermore, infusion of atrial natriuretic peptide (carperitide) 
in patients with heart failure leads to increased adiponectin plasma levels 
(Tanaka et al, 2008). Alternatively, TNFa (among other pro inflammatory 
cytokines) has been suggested to inhibit adiponectin expression in tissue from 
healthy subjects (Bruun et al, 2003; Wang et al, 2006), but perhaps not in 
obese subjects (Degawa Yamauchi et al, 2005). TNFa is known to be elevated Chapter 6: Serial Changes in Adiponectin and BNP in ACS Patients                    156 
   
in conditions such as CHF and ACS (Mizia Stec et al, 2003), and hence, 
speculatively, the inhibitory signal may also be lost in such patients. A recent 
attempt at explaining the physiology behind the reverse epidemiology of 
adiponectin in patients with ACS and CHF has been made, with the authors 
suggesting that elevated levels of adiponectin in these cases represent an 
attempt at counter regulation of systemic inflammation (Rathmann et al, 
2000). Although this is a possibility, the additional possible direct cardio 
protective and metabolic roles of adiponectin in ACS and CHF should not be 
overlooked. Importantly, adiponectin may directly reduce oxidative ischemia 
reperfusion injury (Shibata et al, 2005; Tao et al, 2007; Gonon et al, 2008), 
perhaps alluding to a mechanism whereby elevated BNP, in response to 
cardiac injury, induces an adiponectin mediated cardio protective response. 
Interestingly, this may also be true in silent ischaemia since others have 
suggested elevations in BNP may also occur in silent ischaemia (Rana et al, 
2006; Struthers et al, 2007), an observation potentially explaining why it is a 
better marker than simple echo measures of cardiac dysfunction. Additionally, 
from a metabolic viewpoint, ACS and CHF are often considered to be insulin 
resistant states, although individuals who are insulin resistant without 
cardiovascular complications would be expected to have low levels of 
adiponectin. As we recently suggested (McEntegart, 2007), high levels of 
adiponectin in those with ACS and CHF may be a reflection of a salvage 
mechanism to improve insulin resistance and fatty acid oxidation, perhaps at 
a cost of cachexia in some cases. Regardless of mechanisms, greater cardiac 
disease severity may lead to a greater cardiological and metabolic salvage 
attempt and thus higher adiponectin levels. Alternatively, our speculation 
may be misguided and adiponectin may just be a passive marker of other 
physiological processes, its actions inhibited by peripheral “adiponectin 
resistance.” Limitations of the study require consideration. The group of 442 
ACS patients went on to have 90 endpoint events, and follow up measures are 
based on 51 events in 338 patients, which represents a relatively low power 
for the study and we cannot discount the possibility of type II errors. 
Nevertheless, our data on baseline associations of adiponectin with age and 
female gender (Balion et al, 2008) as well as with BNP (Nakamura et al, 2006; 
McEntegart et al, 2007; Tsutamoto et al, 2007; Kistorp et al, 2005; George et 
al, 2006; Cavusoglu et al, 2006; von Eynatten et al, 2006; Tanaka et al, 2008; Chapter 6: Serial Changes in Adiponectin and BNP in ACS Patients                    157 
   
Schnabel et al, 2008), and the link to endpoints (Schnabel et al, 2008; Cournot 
et al, 2008; Vorovich et al, 2008), is consistent with the literature and suggest 
results are externally valid. Further larger studies with serial measures are 
required to confirm and expand on the potential mechanistic relationships of 
adiponectin, BNP, and cardiac stress. In this study we do not focus on the 
potential clinical utility of any measure of adiponectin or BNP in the ACS 
clinical setting, but on pathophysiological changes in ACS which may instruct 
further clinical studies. 
Of additional interest, the use of genetics (e.g. Mendelian randomisation) may 
help tease out the whether adiponectin is protective, harmful, or passive for 
vascular risk for a variety of patient/cohort groups. In conclusion, we have 
shown for first time by using serial measurements that an increase in plasma 
adiponectin after ACS is strongly related to risk of adverse outcome, but that 
this relationship is not independent of BNP levels. Taken together with 
evidence of apparently paradoxical correlations of adiponectin and BNP at 
baseline, follow up, and in overall change following ACS, our results allude to 
a potential direct or indirect relationship between adiponectin and BNP post 
ACS that requires further investigation. 
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Chapter VII: Discussion 
 
Adiponectin has become a popular molecule for investigation in the ongoing 
search for novel risk markers of diseases associated with the metabolic 
syndrome. It displays insulin sensitising properties as well as having apparent 
anti inflammatory functions. Although it is predominantly released from fat 
cells, its levels are reduced in obese individuals, and the hypothesis is that 
mechanisms associated with insulin resistance, such as inflammation or 
altered adipocyte morphology may be the reason for this. Since the first 
description of the molecule in 1995, the precise role this adipokine plays in 
the onset of disease has been difficult to determine, making it such an 
exciting molecule for investigation.  
 
Many prospective studies have been carried out to determine the role 
adiponectin plays in health and disease, but few have considered the 
laboratory aspects. This thesis has tested adiponectin’s robustness in 
laboratories and it’s associations with CVD using prospective studies. The 
results have shed new insights of potential relevance. The content of this thesis 
has highlighted the importance of considering pre analytical (Results 
summarised in table 7.1) and practical variables in large epidemiological and 
clinical studies. I have shown that one measurement of adiponectin is sufficient 
for use in large epidemiological studies. The reproducibility in measurement of 
this molecule is good and the biological variation is minimal compared to some 
of the other inflammatory cytokines. From our studies, freeze/thaw cycles do 
not affect adiponectin concentrations; we recommend further investigation on 
this. Results from studies involving varied blood processing times and 
temperatures revealed no significant difference in samples left un separated at 
both room temperature (23˚C 25˚C) and in the cold room (4˚C  7˚C) for up to 
6 days. I have validated the use of citrated plasma samples on a commercial 
ELISA (R&D systems adiponectin assay) in our lab, and have also shown that 3 
adiponectin ELISA kits developed by different suppliers correlate well with one 
another. This is important for the comparison of results between studies that 
have employed different commercial kits for adiponectin analysis, although 
some absolute differences suggest the same assay should be used throughout 
any individual study.                                                        
   
Table 7.1 Overview of pre analytical variables for total and HMW adiponectin measurement.  
      
                Sample Type                            Accuracy                      Sample Processing                Freeze thaw                      Variability 
 
             Use in           Use in                  Intra Assay     Inter Assay                  Absolute         Correlations               Absolute         Correlations                     R 
             Serum?           Plasma?                   CV                 CV                     Values Stable?      Stable?               Values Stable?        Stable?     Coefficient (95% CI) 
                                                                                             
                                                 Fridge    Bench      Fridge    Bench           
                           (Pilot study/ larger study)   
Total Adiponectin           +         +*                     < 5%    < 7%        +           +        +           +           +/                  +/+               0.99 (0.98 – 1.00) 
                                                    (Only tested on pilot study) 
HMW Adiponectin           +         +                    < 5%
†             < 6%
†                           ?
         ?         ?
       ?
             +                     +                0.96 (0.78–1.18) 
‡ 
 
 
 
* Also validated in this thesis (chapter 4.2) for use with Citrate Plasma  
† Data taken from ALPCO Diagnostics SOP for the quantitative, selective determination of high, middle and total molecular weight adiponectin in human     
    serum or plasma 
‡ Data taken from Sattar et al, 2008 Chapter 7: Discussion                        160
                              
                    
   
With regards to the clinical studies, our published work as presented in detail 
herein has shown that: 
 
I.  HMW adiponectin is not predictive of CHD events. 
II.  Adiponectin change post ACS correlates with change in BNP and 
elevations in both parameters predict incident events, with BNP 
associations potentially mediating adiponectin’s link to incident 
events. 
 
This work therefore extends current knowledge on both laboratory aspects of 
adiponectin and its associations with vascular disease, although of course, I 
have not examined causal mechanisms but merely reported associations.  
 
Further work 
  
1.  Ideally it would be useful to extend on our laboratory data by 
validating the ALPCO HMW adiponectin ELISA against the gold standard 
method (ultracentrifugation) on a large set of samples (Ideally n>100) 
to confirm our findings.  
 
2.  Further work is required to examine the relationship between HMW 
adiponectin and CHD. Although our study found no link between HMW 
adiponectin and risk of incident vascular events, a larger prospective 
study (therefore offering more statistical power) is needed to confirm 
our findings. 
 
3.  Although research into not mentioned in this thesis, it is still very 
important to note that underlying genes may be responsible for the 
relationships reported in several studies. Whether future studies using 
genetic variations in adiponectin concentrations help determine causal 
pathways, remains to be proven. 
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Appendix 1 
 
 
Manufacturers and suppliers of reagents, hardware and software 
 
1.  Reagents and kits 
 
All R & D kits 
R & D Systems Europe Ltd 
19 Barton Lane 
Abingdon Science Park 
Abingdon  
OX14 3NB 
United Kingdom 
Tel: +44 (0) 1235 529449 
Fax: +44 (0) 1235 533420 
Email: info@RnDSystems.co.uk 
 
All ALPCO Diagnostics kits 
Diagenics Limited 
South House 3 
Bond Avenue 
Bletchley 
Milton Keynes 
MK1 1SW 
United Kingdom 
Tel: 01908 376376 
Fax: 01908 376375 
Email:cs@alpco.com 
 
Mercodia Kits 
Head office in Uppsala, Sweden: 
Sylveniusgatan 8A 
SE 754 50 Uppsala, Sweden 
E mail: info@mercodia.com 
Tel: +46 18 57 00 70 
Fax: +46 18 57 00 80 
Netherlands Contact: Mattias Gareskog 
E mail: mattias.gareskog@mercodia.se 
Tel: +46 18 57 00 77 
                                                                                                            
 
   
   
2.  Equipment 
 
Hamilton Diluter (Microlab 500 series) 
Scientific Laboratory Supplies Ltd 
Unit 17 
Coatbridge Business Centre 
204 Main Street 
Coatbridge 
Lanarkshire 
ML5 3RB 
United Kingdom 
Tel: (01236) 431857 
Fax: (01236) 431050 
Email: info@scientific labs.com 
 
Multiskan Ascent Plate Reader and Ascent Software, Denley minimix 
Plateshaker and Gilson pipettes and Multichannel pipette.   
Thermo Life Sciences 
Unit 5 
The Ringway Centre 
Edison Road 
Basingstoke 
Hampshire 
RG 21 6YH 
Tel: (01256) 817282 
Fax: (01256) 817292 
Website: www.thermols.com 
 
Blood Bottles (Vacutainers) 
BD 
The Danby Building 
Edmund Halley Road, Oxford Science Park 
Oxford   
OX4 4DQ 
United Kingdom 
Tel: +44 1865 748844 
Fax: +44 1865 717313 
Email: bdukvacutainer@europe.bd.com 
Website: www.bd.com/uk  
 
Versa max Plate reader 
Molecular Devices Ltd 
Unit 135, Wharfedale Road 
Winnersh 
Wokingham 
Berkshire 
RG41 5RB 
Tel: 0118 944 8000 
Fax: 0118 9448001 
Website: www.moleculardevices.com                                                                                                            
 
   
   
Appendix 2 
 
 
Calculation of Biological CV 
 
 
Total CV = Total intra person variation (12.9%) 
Methodological CV = Intra assay CV (4.07%) 
 
 
Biological CV =   Total CV – Methodological CV 
                1 – Total CV 
           
          =    0.129 – 0.0407 
1   0.129 
 
      =    0.0883 
       0.871 
 
      =    10.14 % 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                            
 
   
   
Appendix 3 
Kit Inserts 
 
 
 
 
R&D Systems ELISA for total adiponectin 
determination 
 
 
 
Mercodia ELISA for total adiponectin 
determination 
 
 
 
ALPCO Diagnostics ELISA for total, HMW, MMW 
and LMW adiponectin determination 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                            
 
   
   
 
 
                                                                                                            
 
   
                                                                                                              
 
   
                                                                                                              
 
   
                                                                                                              
 
   
                                                                                                              
 
   
                                                                                                              
 
   
                                                                                                              
 
   
                                                                                                              
 
   
                                                                                                              
 
   
                                                                                                              
 
   
                                                                                                              
 
   
                                                                                                              
 
   
                                                                                                              
 
   
                                                                                                              
 
   
                                                                                                              
 
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                            
 
   
   
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                            
 
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                            
 
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                            
 
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                            
 
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                            
 
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                            
 
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                            
 
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                            
 
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                            
 
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                            
 
   
   
 
 
 
 
 
 
 
 
                                                                                                            
 
   
                                                                                                              
 
   
                                                                                                              
 
   
                                                                                                              
 
   
                                                                                                              
 
   
                                                                                                              
 
   
                                                                                                              
 
   
   
Appendix 4 
Papers 
 
 
 
 
￿ High Molecular Weight Adiponectin Is Not 
Associated with Incident Coronary Heart 
Disease in Older Women: A Nested 
Prospective Case-Control Study 
Naveed Sattar, Pauline Watt, Lynne Cherry, 
Shah Ebrahim, George Davey Smith, and 
Debbie A. Lawlor 
 
 
￿ Serial changes in adiponectin and BNP in ACS 
patients: paradoxical associations with each 
other and with prognosis 
Donald S. C. Ang, Paul Welsh, Pauline Watt, 
Scott M. Nelson, Allan Struthers and Naveed 
Sattar. 
                                                                                                            
 
   
                                                                                                              
 
   
                                                                                                              
 
   
                                                                                                              
 
   
                                                                                                              
 
   
                                                                                                              
 
   
                                                                                                              
 
   
                                                                                                              
 
   
                                                                                                              
 
   
                                                                                                              
 
   
                                                                                                              
 
   
                                                                                                              
 
   
                                                                                                              
 
   
   
Appendix 5 
 
 
INFORMED CONSENT FORM 
 
You are being invited to donate a small amount of blood which will be used in 
the Vascular Biochemistry Laboratory, 4
th Floor, Queen Elizabeth Building, 
Glasgow Royal Infirmary for method development or quality control purposes.  
 
No significant risks are associated with taking blood samples. However, it can 
cause minor bruising and only in rare cases may cause inflammation and 
possible infection. The sample will be taken by a member of staff who has 
qualifications in phlebotomy. 
 
Please sign below if you are willing to participate.  
 
 
 
 
 
 
 
 
I agree to donate blood for the above purpose 
 
 
Sign ……………………………    Date …………………………………….. 
 
Print Name ………………………………….. 
 
 
 
 
Researcher 
 
Sign ……………………………    Date …………………………………….. 
 
Print Name ………………………………….. 
 
 
 
 
 
 
 